<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0038">
    <title>22 Streptococcus*</title>
    <sect1 id="ch0038s0001">
      <title>22 Streptococcus*</title>
      <anchor id="ch0038s000001a0001"/>
      <anchor id="ch0038s000000a0001"/>
      <anchor id="ch0038s000000a0002"/>
      <para role="chapterAuthor"><phrase role="center">HEATHER J. ADAM, GREGORY TYRRELL, AND IRENE MARTIN</phrase>
      </para>
      <sect2 id="ch0038s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0038s000001a0002"/>
        <anchor id="ch0038s000000a0003"/>
        <para id="ch0038s000000p0001">The genus<emphasis>Streptococcus</emphasis> currently comprises more than 110 recognized species and subspecies, a number that is continuously rising with the increasing availability of next-generation sequencing technologies. While novel streptococcal species are validly published each year, most of these originate from the oral and gastrointestinal mucosae of various mammals and have so far not been reported as agents of human infections. This chapter focuses on well-known and novel streptococcal species found in human specimens and covers changes that were applied to the taxonomy of streptococci in recent years. Streptococci are <emphasis>Firmicutes</emphasis> of the order <emphasis>Lactobacillales</emphasis> and belong to the family <emphasis>Streptococcaceae</emphasis>. While streptococcal species designation based solely on the hemolysis reaction, colony size, and the presence of Lancefield antigens has several limitations for correct species identification, this traditional streptococcal classification system is well established and still of value to clinical microbiologists and health care providers. It correlates with clinical syndromes caused by different species and enables a first distinction of broad categories of streptococci that is useful for the choice of further tests and guidance of empirical treatments. The information and the identification schemes presented in this chapter therefore adhere in many respects to the phenotypic classification system.</para>
        <para id="ch0038s000000p0002">The classical differentiation of streptococci separates the group of beta-hemolytic streptococci from the group of non-beta-hemolytic streptococcal species. Beta-hemolytic streptococci, also referred to as pyogenic streptococci, include the human-pathogenic species<emphasis>Streptococcus pyogenes, S. agalactiae, S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis>, and a number of primarily veterinary pathogens. The designation “pyogenic streptococci” is more precise, since the group includes species that are non-beta-hemolytic, such as <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>dysgalactiae</emphasis>, and the term excludes beta-hemolytic strains of the <emphasis>S. anginosus</emphasis> group, which belong to the viridans streptococcal group (<anchor id="ch0038s000000a0004"/><link linkend="ch0038s000000a0007">Table 1</link>). The small colony size of streptococci from the <emphasis>S. anginosus</emphasis> group (≤0.5 mm) helps to distinguish them from the large-colony-forming (&gt;0.5 mm) streptococci of the pyogenic group. Species from the pyogenic or beta-hemolytic group are further characterized by the presence of Lancefield antigens, which do not always correlate with the proper streptococcal species designations (<anchor id="ch0038s000000a0005"/><link linkend="ch0038s000000a0012">Table 2</link>).</para>
        <para id="ch0038s000000p0003">The group of nonpyogenic streptococci includes mostly alpha-hemolytic as well as nonhemolytic and even beta-hemolytic streptococcal species from the large category of viridans group streptococci. In a study of the genus<emphasis>Streptococcus</emphasis> based on sequence comparisons of small-subunit (16S) rRNA genes, five species groups of viridans group streptococci were demonstrated in addition to the pyogenic group (beta-hemolytic, large-colony formers) (<link linkend="ch0038s000000li0001">1</link>). These nonpyogenic groups were designated the <emphasis>S. mitis</emphasis> group, the <emphasis>S. anginosus</emphasis> group, the <emphasis>S. mutans</emphasis> group, the <emphasis>S. salivarius</emphasis> group, and the <emphasis>S. equinus</emphasis> group (previously known as <emphasis>S. bovis</emphasis> group) (<link linkend="ch0038s000000a0007">Table 1</link>). Several streptococcal species were not unequivocally assigned and remain ungrouped (<link linkend="ch0038s000000li0002">2</link>).</para>
        <para id="ch0038s000000p0004">Among viridans group streptococci, the<emphasis>S. mitis</emphasis> group represents the largest group of closely related species. Currently, it comprises <emphasis>S. australis, S. cristatus, S. gordonii, S. infantis, S. lactarius, S. massiliensis, S. mitis, S. oralis</emphasis> subsp. <emphasis>dentisani, S. oralis</emphasis> subsp. <emphasis>oralis, S. oralis</emphasis> subsp. <emphasis>tigurinus, S. parasanguinis, S. peroris, S. pneumoniae, S. pseudopneumoniae, S. rubneri, S. sanguinis, S. sinensis</emphasis>, and several veterinary species. The classification and nomenclature of this group have been a source of considerable confusion in the past. Among the changes that were made is the reclassification of the original <emphasis>S. mitis</emphasis> type strain as an <emphasis>S. gordonii</emphasis> strain and the subsequent replacement by a new <emphasis>S. mitis</emphasis> type strain (NCTC12261). A recent comprehensive study based on the analysis of whole-genome sequence data reevaluated species designations of the <emphasis>S. mitis</emphasis> group and led to several taxonomic changes. These include the reassignment of <emphasis>S. oligofermentans</emphasis> as <emphasis>S. cristatus</emphasis> and the reclassification of <emphasis>S. tigurinus</emphasis> as a subspecies of <emphasis>S. oralis</emphasis> (<emphasis>S. oralis</emphasis> subsp. <emphasis>tigurinus</emphasis>) (<link linkend="ch0038s000000li0003">3</link>). While phenotypic characterization and taxonomic considerations place <emphasis>S. pneumoniae</emphasis> in the <emphasis>S. mitis</emphasis> group (<link linkend="ch0038s000000li0001">1</link>), it is discussed separately throughout this chapter due to its clinical significance. However, the relationship of <emphasis>S. pneumoniae</emphasis> to other species of the <emphasis>S. mitis</emphasis> group is so close that 16S rRNA gene analysis reveals &gt;99% identity to the nucleotide sequences of <emphasis>S. mitis</emphasis> and <emphasis>S. oralis</emphasis>. Similar difficulties may be encountered in matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) analysis, which demonstrates the need for other techniques to allow precise species designations within this group (<link linkend="ch0038s000000li0003">3</link>).</para>
        <anchor id="ch0038s000000a0006"/>
        <beginpage pagenum="430"/>
        <table id="ch0038s000000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0038s000000a0007"/><link linkend="ch0038s000000a0004">TABLE 1</link></phrase></emphasis> Streptococcal species belonging to the viridans group and their current association with larger taxonomic clusters
</title>
          
          <tgroup cols="5">
            <tbody>
              <row>
                <entry><emphasis>S. mitis</emphasis> group<superscript><emphasis><anchor id="ch0038s000000a0008"/><link linkend="ch0038s000000a0009">a</link></emphasis></superscript></entry>
                <entry><emphasis>S. anginosus</emphasis> group</entry>
                <entry><emphasis>S. mutans</emphasis> group<superscript><emphasis><link linkend="ch0038s000000a0009">a</link></emphasis></superscript></entry>
                <entry><emphasis>S. salivarius</emphasis> group</entry>
                <entry><emphasis>S. equinus</emphasis> group</entry>
              </row>
              <row>
                <entry><emphasis>S. australis</emphasis>
                </entry>
                <entry><emphasis>S. anginosus</emphasis> subsp. <emphasis>anginosus</emphasis></entry>
                <entry><emphasis>S. criceti</emphasis>
                </entry>
                <entry><emphasis>S. vestibularis</emphasis>
                </entry>
                <entry><emphasis>S. equinus</emphasis>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. cristatus</emphasis>
                </entry>
                <entry><emphasis>S. anginosus</emphasis> subsp. <emphasis>whileyi</emphasis></entry>
                <entry><emphasis>S. downei</emphasis>
                </entry>
                <entry><emphasis>S. salivarius</emphasis> subsp. <emphasis>salivarius</emphasis></entry>
                <entry><emphasis>S. gallolyticus</emphasis> subsp<emphasis>. gallolyticus</emphasis></entry>
              </row>
              <row>
                <entry><emphasis>S. gordonii</emphasis>
                </entry>
                <entry><emphasis>S. constellatus</emphasis> subsp. <emphasis>constellatus</emphasis></entry>
                <entry><emphasis>S. mutans</emphasis>
                </entry>
                <entry><emphasis>S. salivarius</emphasis> subsp. <emphasis>thermophilus</emphasis></entry>
                <entry><emphasis>S. gallolyticus</emphasis> subsp<emphasis>. pasteurianus</emphasis></entry>
              </row>
              <row>
                <entry><emphasis>S. infantis</emphasis>
                </entry>
                <entry><emphasis>S. constellatus</emphasis> subsp. <emphasis>pharyngis</emphasis></entry>
                <entry><emphasis>S. ratti</emphasis>
                </entry>
                <entry/>
                <entry><emphasis>S. gallolyticus</emphasis> subsp<emphasis>. macedonicus</emphasis></entry>
              </row>
              <row>
                <entry><emphasis>S. lactarius</emphasis>
                </entry>
                <entry><emphasis>S. constellatus</emphasis> subsp. <emphasis>viborgensis</emphasis></entry>
                <entry><emphasis>S. sobrinus</emphasis>
                </entry>
                <entry/>
                <entry><emphasis>S. infantarius</emphasis> subsp<emphasis>. infantarius</emphasis></entry>
              </row>
              <row>
                <entry><emphasis>S. massiliensis</emphasis>
                </entry>
                <entry><emphasis>S. intermedius</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry><emphasis>S. lutetiensis</emphasis>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. mitis</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry><emphasis>S. alactolyticus</emphasis>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. oralis</emphasis> subsp<emphasis>. dentisani</emphasis></entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. oralis</emphasis> subsp<emphasis>. oralis</emphasis></entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. oralis</emphasis> subsp<emphasis>. tigurinus</emphasis></entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. parasanguinis</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. peroris</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. pneumoniae</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. pseudopneumoniae</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. rubneri</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. sanguinis</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><emphasis>S. sinensis</emphasis>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0009"/><link linkend="ch0038s000000a0008">a</link></emphasis></superscript> Excluding veterinary species.</para>
        <para id="ch0038s000000p0005">The small-colony-forming<emphasis>S. anginosus</emphasis> group consists of the species <emphasis>S. anginosus, S. constellatus</emphasis>, and <emphasis>S. intermedius</emphasis>. <emphasis>S. anginosus</emphasis> is divided into the subspecies <emphasis>S. anginosus</emphasis> subsp. <emphasis>anginosus</emphasis> and <emphasis>S. anginosus</emphasis> subsp. <emphasis>whileyi</emphasis>. <emphasis>S. constellatus</emphasis> comprises three subspecies, <emphasis>S. constellatus</emphasis> subsp. <emphasis>constellatus, S. constellatus</emphasis> subsp. <emphasis>pharyngis</emphasis>, and <emphasis>S. constellatus s</emphasis>ubsp. <emphasis>viborgensis</emphasis> (<link linkend="ch0038s000000li0004">4</link>). The <emphasis>S. mutans</emphasis> group comprises the species <emphasis>S. mutans, S. sobrinus, S. criceti, S. ratti, S. downei</emphasis>, and numerous species that have been identified only from animals thus far (<emphasis>S. ferus, S. macacae, S. hyovaginalis</emphasis>, and <emphasis>S. devriesei</emphasis>). Three distinct species form the <emphasis>S. salivarius</emphasis> group: <emphasis>S. salivarius</emphasis> subsp. <emphasis>salivarius, S. vestibularis</emphasis>, and <emphasis>S. salivarius</emphasis> subsp. <emphasis>thermophilus</emphasis>, which is found in dairy products. The whole <emphasis>S. salivarius</emphasis> group is closely related to the <emphasis>S. equinus</emphasis> group. Some streptococcal species that are currently part of the <emphasis>S. equinus</emphasis> group (<emphasis>S. infantarius</emphasis> and <emphasis>S. alactolyticus</emphasis>) (<link linkend="ch0038s000000li0005">5</link>) were formerly assigned to the <emphasis>S. salivarius</emphasis> group (<link linkend="ch0038s000000li0002">2</link>).</para>
        <para id="ch0038s000000p0006">The<emphasis>S. equinus</emphasis> group has undergone extensive taxonomic changes (<link linkend="ch0038s000000li0005">5</link>, <link linkend="ch0038s000000li0006">6</link>) in the past. These changes were made because DNA-DNA reassociation studies revealed considerable heterogeneity among the human isolates previously described as <emphasis>S. bovis</emphasis> biotypes. Four DNA clusters were recognized, resulting in the current species and subspecies designations: <emphasis>S. equinus</emphasis> (DNA cluster 1), <emphasis>S. gallolyticus</emphasis> subsp. <emphasis>gallolyticus, S. gallolyticus</emphasis> subsp. <emphasis>pasteurianus</emphasis>, and <emphasis>S. gallolyticus</emphasis> subsp. <emphasis>macedonicus</emphasis> (DNA cluster II), S. <emphasis>infantarius</emphasis> and <emphasis>S. lutetiensis</emphasis> (DNA cluster III), and <emphasis>S. alactolyticus</emphasis> (DNA cluster IV). The species naming within this group remains complex, with unresolved issues. Specifically, <emphasis>S. lutetiensis</emphasis> (<link linkend="ch0038s000000li0007">7</link>) was proposed as a new species with the type strain previously published as <emphasis>S. infantarius</emphasis> subsp. <emphasis>coli</emphasis> (<link linkend="ch0038s000000li0006">6</link>); however, the <emphasis>S. infantarius</emphasis> subsp. <emphasis>coli</emphasis> proposal did not correctly designate the isolate as a type strain, leading to ongoing consideration of the correct nomenclature.</para>
      </sect2>
      <sect2 id="ch0038s0001s0002">
        <title>DESCRIPTION OF THE GENUS</title>
        <anchor id="ch0038s000001a0003"/>
        <anchor id="ch0038s000000a0010"/>
        <para id="ch0038s000000p0007">Bacterial species belonging to the genus<emphasis>Streptococcus</emphasis> are catalase-negative, Gram-positive cocci of less than 2 μm that tend to grow in chains in liquid media. Most species of the genus <emphasis>Streptococcus</emphasis> have a low G+C content of DNA, ranging between 34 and 46%. The cell wall composition is typical of Gram-positive bacteria and consists mainly of peptidoglycan with glucosamine and muramic acid as amino sugars and galactosamine as a variable component. A variety of carbohydrates, surface protein antigens, and teichoic acid are attached to the cell wall and are, among other characteristics, responsible for intra- and interspecies differences among streptococci. Streptococci are facultatively anaerobic bacteria. Due to a lack of heme compounds, streptococci are incapable of respiratory metabolism. Glucose and other carbohydrates are metabolized fermentatively, with lactic acid as the major metabolic end product. The addition of glucose or other carbohydrates to liquid medium enhances growth but lowers the pH, resulting in growth inhibition unless the medium is highly buffered (e.g., Todd-Hewitt broth). Leucine aminopeptidase is produced by all streptococci and enterococci but can also be found in lactococci, pediococci, and other catalase-negative Gram-positive cocci. It helps to distinguish these species from the leucine aminopeptidase-negative <emphasis>Aerococcus</emphasis> species and <emphasis>Leuconostoc</emphasis>. All streptococci are catalase negative upon exposure to 3% hydrogen peroxide, with the exception of <emphasis>S. didelphis</emphasis>, a veterinary pathogen (<link linkend="ch0038s000000li0008">8</link>).</para>
        <anchor id="ch0038s000000a0011"/>
        <beginpage pagenum="431"/>
        <table id="ch0038s000000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0038s000000a0012"/><link linkend="ch0038s000000a0005">TABLE 2</link></phrase></emphasis> Phenotypic characteristics of beta-hemolytic streptococci<superscript><emphasis><anchor id="ch0038s000000a0013"/><link linkend="ch0038s000000a0021">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="11">
            <tbody>
              <row>
                <entry>Species</entry>
                <entry><phrase role="center">Lancefield group</phrase>
                </entry>
                <entry><phrase role="center">Colony size<superscript><emphasis><anchor id="ch0038s000000a0014"/><link linkend="ch0038s000000a0022">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">Hosts</phrase>
                </entry>
                <entry><phrase role="center">Bacitracin susceptibility</phrase>
                </entry>
                <entry><phrase role="center">PYR<superscript><emphasis><anchor id="ch0038s000000a0015"/><link linkend="ch0038s000000a0023">c</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">CAMP<superscript><emphasis><anchor id="ch0038s000000a0016"/><link linkend="ch0038s000000a0024">d</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">VP<superscript><emphasis><anchor id="ch0038s000000a0017"/><link linkend="ch0038s000000a0025">e</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">Hippurate hydrolysis</phrase>
                </entry>
                <entry><phrase role="center">Trehalose</phrase>
                </entry>
                <entry><phrase role="center">Sorbitol</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. pyogenes</emphasis>
                </entry>
                <entry>A</entry>
                <entry>Large</entry>
                <entry>Humans</entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. agalactiae</emphasis>
                </entry>
                <entry>B</entry>
                <entry>Large</entry>
                <entry>Humans, cows</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. dysgal</emphasis><emphasis>actia</emphasis><emphasis>e</emphasis> subsp. <emphasis>dy</emphasis><emphasis>sgalactia</emphasis><emphasis>e</emphasis><superscript><emphasis><anchor id="ch0038s000000a0018"/><link linkend="ch0038s000000a0026">f</link></emphasis></superscript></entry>
                <entry>C</entry>
                <entry>Large</entry>
                <entry>Animals</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis></entry>
                <entry>A, C, G, L</entry>
                <entry>Large</entry>
                <entry>Humans (animals)</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. equi</emphasis> subsp. <emphasis>equi</emphasis></entry>
                <entry>C</entry>
                <entry>Large</entry>
                <entry>Animals</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. equi</emphasis> subsp. <emphasis>zooepidemicus</emphasis><superscript><emphasis><anchor id="ch0038s000000a0019"/><link linkend="ch0038s000000a0027">g</link></emphasis></superscript></entry>
                <entry>C</entry>
                <entry>Large</entry>
                <entry>Animals (humans)</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. canis</emphasis>
                  <superscript>
                    <emphasis>
                      <link linkend="ch0038s000000a0027">g</link>
                    </emphasis>
                  </superscript>
                </entry>
                <entry>G</entry>
                <entry>Large</entry>
                <entry>Dogs (humans)</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. anginosus</emphasis> group<superscript><emphasis><anchor id="ch0038s000000a0020"/><link linkend="ch0038s000000a0028">h</link></emphasis></superscript></entry>
                <entry>A, C, G, F, none</entry>
                <entry>Small</entry>
                <entry>Humans</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>S. porcinus</emphasis>
                  <superscript>
                    <emphasis>
                      <link linkend="ch0038s000000a0027">g</link>
                    </emphasis>
                  </superscript>
                </entry>
                <entry>E, P, U, V, none</entry>
                <entry>Large</entry>
                <entry>Swine</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0021"/><link linkend="ch0038s000000a0013">a</link></emphasis></superscript>+, positive; −, negative; V, variable.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0022"/><link linkend="ch0038s000000a0014">b</link></emphasis></superscript>Large colony size refers to colonies of &gt;0.5 mm after 24 h incubation, whereas small colony size is &lt;0.5 mm.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0023"/><link linkend="ch0038s000000a0015">c</link></emphasis></superscript>Presence of the enzyme pyrrolidonyl aminopeptidase.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0024"/><link linkend="ch0038s000000a0016">d</link></emphasis></superscript>CAMP factor reaction (cohemolysis in the presence of the <emphasis>Staphylococcus aureus</emphasis> beta-hemolysin).</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0025"/><link linkend="ch0038s000000a0017">e</link></emphasis></superscript>Voges-Proskauer test (formation of acetoin from glucose fermentation).</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0026"/><link linkend="ch0038s000000a0018">f</link></emphasis></superscript><emphasis>S. dysgalactiae</emphasis> subsp<emphasis>. dysgalactiae</emphasis> is alpha-hemolytic on sheep blood agar plates.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0027"/><link linkend="ch0038s000000a0019">g</link></emphasis></superscript><emphasis>S. equi</emphasis> subsp. <emphasis>zooepidemicus, S. canis</emphasis>, and <emphasis>S. porcinus</emphasis> are primarily animal pathogens that are only rarely isolated from humans. Human <emphasis>S. porcinus</emphasis> isolates most likely belong to the novel species <emphasis>S. pseudoporcinus</emphasis>.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0028"/><link linkend="ch0038s000000a0020">h</link></emphasis></superscript>Species included in the <emphasis>S. anginosus</emphasis> group can be beta-hemolytic, alpha-hemolytic, or nonhemolytic on sheep blood agar plates.</para>
      </sect2>
      <sect2 id="ch0038s0001s0003">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0038s000001a0004"/>
        <anchor id="ch0038s000000a0029"/>
        <para id="ch0038s000000p0008">Streptococci can cause infections in humans and in many animal species, including mammals and fish. Different species of streptococci are frequently found as commensal bacteria on mucous membranes. Occasionally, streptococci are present as transient skin microbiota organisms. Several species exhibit a high virulence potential, but even the highly pathogenic streptococcal species are frequently found as colonizing strains.<emphasis>S. pneumoniae</emphasis> is the most frequent cause of severe pneumonia and pneumonia deaths worldwide, estimated to have contributed to over a million deaths in 2016 (<link linkend="ch0038s000000li0009">9</link>). CDC’s Active Bacterial Core (ABC) surveillance program estimated that <emphasis>S. pneumoniae</emphasis> caused approximately 30,300 invasive infections in the United States in 2019, leading to an estimated 3,250 deaths (<ulink url="https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf">https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf</ulink>). It colonizes the nasopharynx in asymptomatic carriers. The carriage rate for <emphasis>S. pneumoniae</emphasis> is age dependent, with detection rates of 30 to 70% in young children and below 5% in healthy adults (<link linkend="ch0038s000000li0010">10</link>). Colonization rates for adults living in households with preschool-age children are higher, indicating household transmission between parents and their children. Pyogenic streptococci are also encountered as colonizing strains. Asymptomatic pharyngeal colonization with <emphasis>S. pyogenes</emphasis> occurs in less than 5% of adults, and urogenital and gastrointestinal colonization with <emphasis>S. agalactiae</emphasis> occurs in 10 to 30% of the adult population.</para>
        <para id="ch0038s000000p0009">The global prevalence of severe group A<emphasis>Streptococcus</emphasis> (GAS) disease is at least 1.78 million cases annually with at least 517,000 deaths each year due to severe GAS diseases (e.g., acute rheumatic fever, rheumatic heart disease, poststreptococcal glomerulonephritis, and invasive infections) (<link linkend="ch0038s000000li0011">11</link>). There is a persistently high disease burden in low-resource nations, and over the past few decades, there has been a resurgence of scarlet fever, with large outbreaks in the United Kingdom and Asia (<link linkend="ch0038s000000li0012">12</link>). ABC surveillance of 34,577,823 people in the United States estimates that <emphasis>S. pyogenes</emphasis> caused 25,050 cases of invasive disease and 2,250 deaths in 2019, with the highest attack rates in people older than 65 years (<ulink url="https://www.cdc.gov/abcs/downloads/GAS_Surveillance_Report_2019.pdf">https://www.cdc.gov/abcs/downloads/GAS_Surveillance_Report_2019.pdf</ulink>). Invasive infections due to <emphasis>S. agalactiae</emphasis> were estimated at 32,700 cases and 2,000 deaths in 2019 (<ulink url="https://www.cdc.gov/abcs/downloads/GBS_Surveillance_Report_2019.pdf">https://www.cdc.gov/abcs/downloads/GBS_Surveillance_Report_2019.pdf</ulink>). Reflecting the ongoing changes in the epidemiology of group B streptococcal disease, the majority of invasive infections were observed in adults above 50 years of age and the highest rates were observed in children &lt;1 year of age (57.0/100,000).</para>
        <para id="ch0038s000000p0010">Transmission of streptococcal infections occurs by various routes. Pathogenic species such as<emphasis>S. pyogenes</emphasis> and <emphasis>S. pneumoniae</emphasis>, which colonize the upper respiratory tract, are primarily transmitted through direct contact or droplets. Transmission can first lead to colonization with the potential for the development of a subsequent infection. <emphasis>S. agalactiae</emphasis> transmission from mother to child can occur during birth and within the first seven days of life. Transmission of <emphasis>S. agalactiae</emphasis> to the neonate after this time period is not as well understood. Another streptococcal species transmitted from mother to child is the tooth decay-causing species <emphasis>S. mutans</emphasis>; transmission occurs during early infancy, probably through oral secretions.</para>
        <para id="ch0038s000000p0011">Streptococcal infections are not classical zoonoses. Most species have a preferred host, while occasional animal-to-human transmissions do occur, as in the case of<emphasis>S. suis</emphasis> and <emphasis>S. agalactiae</emphasis> (<link linkend="ch0038s000000li0013">13</link>, <link linkend="ch0038s000000li0014">14</link>). Genotypic and phenotypic analyses of animal and human strains show distinct differences between strains causing human infections and veterinary isolates. Human beta-hemolytic group C and group G streptococci are defined as <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis>, while group C and L streptococcal animal isolates are classified as <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>dysgalactiae</emphasis>. Animal group G streptococcal strains are classified as <emphasis>S. canis</emphasis> (<link linkend="ch0038s000000li0015">15</link>, <link linkend="ch0038s000000li0016">16</link>). Other closely related group C streptococcal veterinary species are <emphasis>S. equi</emphasis> subsp. <emphasis>equi</emphasis> and <emphasis>S. equi</emphasis> subsp. <emphasis>zooepidemicus</emphasis>. The predominant reservoir for <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> strains is the human host, and transmission usually occurs among humans.</para>
        <anchor id="ch0038s000000a0030"/>
        <beginpage pagenum="432"/>
      </sect2>
      <sect2 id="ch0038s0001s0004">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0038s000001a0005"/>
        <anchor id="ch0038s000000a0031"/>
      </sect2>
    </sect1>
    <sect1 id="ch0038s0002">
      <title>S. pyogenes (Group A Streptococci)</title>
      <anchor id="ch0038s000002a0001"/>
      <anchor id="ch0038s000000a0032"/>
      <para id="ch0038s000000p0012"><emphasis>S. pyogenes</emphasis> colonizes the human throat and skin and has developed complex virulence mechanisms to avoid host defenses (<link linkend="ch0038s000000li0017">17</link>). The upper respiratory tract and skin lesions serve as primary focal sites of infections and principal reservoirs of transmission. Humans are the only known natural host for <emphasis>S. pyogenes</emphasis>. This bacterium can cause superficial and deep infections due to toxin-mediated and immunologically mediated mechanisms. <emphasis>S. pyogenes</emphasis> is the most common cause of bacterial pharyngitis and impetigo. In the past, <emphasis>S. pyogenes</emphasis> was a common cause of puerperal sepsis; however, this is now uncommon. <emphasis>S. pyogenes</emphasis> is also a major cause of invasive infections, including bacteremia, sepsis, septic arthritis, and soft tissue infections, such as erysipelas, cellulitis, and necrotizing fasciitis. Less common presentations include myositis, osteomyelitis, pneumonia, meningitis, endocarditis, and neonatal infections. One or more erythrogenic exotoxins produced by <emphasis>S. pyogenes</emphasis> may cause a confluent erythematous sandpaper-like rash characteristic of scarlet fever. While systemic toxic effects occur rarely with scarlet fever, severe clinical manifestations such as streptococcal toxic shock syndrome (STSS) may result from massive superantigen-induced cytokine production. Nonsuppurative complications include poststreptococcal glomerulonephritis and acute rheumatic fever. Tropical and subtropical regions such as those in Australia and New Zealand have experienced high rates of acute rheumatic fever and rheumatic heart disease among the indigenous populations due to <emphasis>S. pyogenes</emphasis>. In these populations, there is mounting evidence that <emphasis>S. pyogenes</emphasis> skin infections are significant contributors to these diseases (<link linkend="ch0038s000000li0018">18</link>). In addition, glomerulonephritis has been shown to be linked with skin infections due to <emphasis>S. pyogenes</emphasis>. <emphasis>S. pyogenes</emphasis> has also been associated with pediatric autoimmune neuropsychiatric disorders (PANDAS) (<link linkend="ch0038s000000li0019">19</link>). This is an area of active investigation.</para>
      <para id="ch0038s000000p0013">Causes of the emergence of STSS, frequently accompanied by necrotizing fasciitis, and the resurgence of invasive<emphasis>S. pyogenes</emphasis> infections since the mid-1980s are now being elucidated due in large part to whole-genome sequencing. To understand the possible mechanisms for this surge in invasive disease, investigators performed whole-genome sequencing (WGS) on a large collection (over 3,600 isolates) of <emphasis>S. pyogenes emm</emphasis>1 strains collected from various locations (<link linkend="ch0038s000000li0020">20</link>). <emphasis>S. pyogenes</emphasis> can be typed based on the <emphasis>emm</emphasis> gene (see “Typing Systems”). Comparative analysis of genomes found that three important genetic changes had occurred temporally in an <emphasis>emm1</emphasis> clone of <emphasis>S. pyogenes</emphasis>, resulting in a highly virulent <emphasis>emm1</emphasis> strain that has caused millions of infections worldwide. These changes occurred in a <emphasis>S. pyogenes</emphasis> precursor cell that contained a phage encoding an extracellular DNase (streptococcal DNase D2 [SdaD2]) (<link linkend="ch0038s000000li0020">20</link>). The subsequent acquisition by this precursor cell of a phage encoding SpeA2 (a variant of SpeA1) followed by the horizontal gene transfer of a chromosomal region encoding the toxins NAD<superscript>+</superscript>-glycohydrolase and streptolysin O are thought to have led to the emergence and rapid spread of a highly virulent epidemic M1 <emphasis>S. pyogenes</emphasis> clone (<link linkend="ch0038s000000li0020">20</link>). Further work has also shown that the risk of development of severe invasive infection in close contacts of patients with invasive <emphasis>S. pyogenes</emphasis> disease is estimated to be 200 times greater than for the general population, with most contacts being asymptomatically colonized (<link linkend="ch0038s000000li0021">21</link>).</para>
    </sect1>
    <sect1 id="ch0038s0003">
      <title>S. agalactiae (Group B Streptococci)</title>
      <anchor id="ch0038s000003a0001"/>
      <anchor id="ch0038s000000a0033"/>
      <para id="ch0038s000000p0014"><emphasis>S. agalactiae</emphasis> is a major cause of invasive neonatal infections. Newborns usually acquire the bacteria during delivery, although prenatal transmission occurs and is associated with preterm labor and stillbirth. Neonatal infections present as two different clinical entities: early-onset neonatal disease, characterized by sepsis, pneumonia, and meningitis within the first 7 days of life, and late-onset disease, with meningitis and sepsis between 7 days and 3 months of age. The most important risk factor for the development of invasive neonatal disease is the colonization of the maternal urogenital or gastrointestinal tract, which is found in 10 to 30% of pregnant women. Prevention of early-onset neonatal disease can be achieved in the majority of cases by administration of intrapartum antibiotic prophylaxis starting at least 4 h before delivery. CDC recommendations for <emphasis>S. agalactiae</emphasis> screening to prevent neonatal infections were first issued in 1996 and updated in 2010 (<link linkend="ch0038s000000li0022">22</link>). In 2019, the responsibility for the guidelines for prevention of early-onset disease, management of infants at risk for <emphasis>S. agalactiae</emphasis> disease, and laboratory detection and identification of <emphasis>S. agalactiae</emphasis> was transferred to three organizations: the American College of Obstetricians and Gynecologists (<link linkend="ch0038s000000li0023">23</link>), the American Academy of Pediatrics (<link linkend="ch0038s000000li0024">24</link>), and the American Society for Microbiology (ASM) (<link linkend="ch0038s000000li0025">25</link>). These guidelines resulted in a substantial decline of early-onset neonatal disease but no significant impact on late-onset disease. Invasive <emphasis>S. agalactiae</emphasis> infections of adult patients are increasing and are typically observed in elderly patients or in immunocompromised patients with alcoholism, diabetes mellitus, and cancer (<link linkend="ch0038s000000li0026">26</link>, <link linkend="ch0038s000000li0027">27</link>). Frequent clinical syndromes in adults consist of bacteremia without a primary focus and skin, soft tissue, and osteoarticular infections. The spectrum includes pneumonia, endocarditis, meningitis, and urinary tract infections.</para>
    </sect1>
    <sect1 id="ch0038s0004">
      <title>S. dysgalactiae subsp. equisimilis (Human Group C and G Streptococci)</title>
      <anchor id="ch0038s000004a0001"/>
      <anchor id="ch0038s000000a0034"/>
      <para id="ch0038s000000p0015">Human isolates of large-colony-forming beta-hemolytic streptococci harboring the Lancefield group C or group G antigens belong to this species. While most isolates of this species possess either the Lancefield group C or G antigen, strains harboring the Lancefield group L as well as the group A antigen have been described. The clinical spectrum of disease caused by<emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> resembles infections caused by <emphasis>S. pyogenes</emphasis> (<link linkend="ch0038s000000li0015">15</link>). The responsible strains harbor genes similar to virulence factor genes of <emphasis>S. pyogenes</emphasis>, such as <emphasis>emm</emphasis>-like genes. <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> can be isolated from upper respiratory tract infections, skin infections, soft tissue infections, and invasive infections such as necrotizing fasciitis, STSS, bacteremia, arthritis, osteomyelitis, and endocarditis. Convincing reports about scarlet fever due to <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> have not been published. Similar to <emphasis>S. pyogenes</emphasis>, cases of glomerulonephritis and acute rheumatic fever have been reported following <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> infections (<link linkend="ch0038s000000li0028">28</link>, <link linkend="ch0038s000000li0029">29</link>).</para>
      <anchor id="ch0038s000000a0035"/>
      <beginpage pagenum="433"/>
    </sect1>
    <sect1 id="ch0038s0005">
      <title>S. pneumoniae</title>
      <anchor id="ch0038s000005a0001"/>
      <anchor id="ch0038s000000a0036"/>
      <para id="ch0038s000000p0016"><emphasis>S. pneumoniae</emphasis> is described separately in this section due to its clinical features, which distinguish it from other species of the <emphasis>S. mitis</emphasis> group. <emphasis>S. pneumoniae</emphasis> accounts for the vast majority of cases of community-acquired pneumonia in adults (81 to 87%), up to 16% of whom have positive blood cultures (<link linkend="ch0038s000000li0030">30</link>). <emphasis>S. pneumoniae</emphasis> is also a major cause of meningitis, leading to high morbidity and mortality in pediatric and adult patients. Other infections due to <emphasis>S. pneumoniae</emphasis> include noninvasive diseases such as sinusitis and acute otitis media. Invasive diseases include bacteremia, peritonitis, endocarditis, and meningitis. <emphasis>S. pneumoniae</emphasis> can colonize the upper respiratory tract, especially in children, without evidence of infection. The main virulence factor of <emphasis>S. pneumoniae</emphasis> is its polysaccharide capsule, of which there are now 100 types (<link linkend="ch0038s000000li0031">31</link>). The polysaccharide capsule is the pneumococcal antigen in pneumococcal vaccines. Unlike <emphasis>S. pyogenes</emphasis> and <emphasis>S. agalactiae</emphasis>, prevention of pneumococcal infections can be achieved by immunization. There are currently two types of polysaccharide-based vaccines in use for the prevention of pneumococcal disease. One vaccine, containing only polysaccharides, is composed of 23 capsule types (PPSV23) and is targeted toward adults. The second type are polysaccharide-protein conjugate vaccines, which have been developed to include increasing numbers of capsular types since PCV7 was first released in 2000. PCV10 and PCV13, composed of 10 and 13 capsular types, respectively, are currently available and are targeted toward children. In 2021, recommendations were updated to include PCV15 and PCV20, 15- and 20-valent conjugate vaccines, respectively, for adults in the United States (<link linkend="ch0038s000000li0032">32</link>). Widespread use of the protein conjugate vaccines in children has resulted in large reductions of invasive pneumococcal infections in this population since its introduction in the early 2000s (<link linkend="ch0038s000000li0033">33</link>, <link linkend="ch0038s000000li0034">34</link>). Vaccination with the protein-conjugate vaccines has also resulted in a general decrease of rates of nasopharyngeal colonization with vaccine-included serotypes (<link linkend="ch0038s000000li0035">35</link>). It also lowers the burden of invasive disease in children (<link linkend="ch0038s000000li0033">33</link>, <link linkend="ch0038s000000li0036">36</link>). <emphasis>S. pseudopneumoniae</emphasis> is closely related to <emphasis>S. pneumoniae</emphasis> but has been identified as a distinct species. Isolates of <emphasis>S. pseudopneumoniae</emphasis> are nonencapsulated, insoluble in bile, and optochin susceptible only when incubated in ambient air. <emphasis>S. pseudopneumoniae</emphasis> causes respiratory tract infections in patients with predisposing conditions such as chronic obstructive pulmonary disease (<link linkend="ch0038s000000li0037">37</link>, <link linkend="ch0038s000000li0038">38</link>).</para>
    </sect1>
    <sect1 id="ch0038s0006">
      <title>S. mitis Group Other than S. pneumoniae</title>
      <anchor id="ch0038s000006a0001"/>
      <anchor id="ch0038s000000a0037"/>
      <para id="ch0038s000000p0017">Members of the large and heterogeneous<emphasis>S. mitis</emphasis> group (<link linkend="ch0038s000000a0007">Table 1</link>) are regular commensals of the oral cavity, the gastrointestinal tract, and the female genital tract. The <emphasis>S. mitis</emphasis> group can be found as transient members of the microbiota of the normal skin and may represent contaminants when isolated from blood cultures. At the same time, these species are the most frequently isolated bacteria in bacterial endocarditis in native-valve and, less frequently, in prosthetic-valve infections. Careful evaluation of the clinical situation is therefore crucial to correctly interpret the clinical significance of blood culture isolates from the <emphasis>S. mitis</emphasis> group. In neutropenic patients, species from the <emphasis>S. mitis</emphasis> group are often responsible for life-threatening sepsis and pneumonia cases following immunosuppression by chemotherapy (<link linkend="ch0038s000000li0038">38</link>). Treatment of these infections is further complicated by high penicillin resistance rates.</para>
    </sect1>
    <sect1 id="ch0038s0007">
      <title>S. anginosus Group</title>
      <anchor id="ch0038s000007a0001"/>
      <anchor id="ch0038s000000a0038"/>
      <para id="ch0038s000000p0018">Species in this group (<emphasis>S. anginosus, S. constellatus</emphasis>, and <emphasis>S. intermedius</emphasis>) are commensals of the oropharyngeal, urogenital, and gastrointestinal microbiotas. These organisms are associated with abscess formation in the brain, oropharynx, or peritoneal cavity. In addition, the <emphasis>S. anginosus</emphasis> group has been implicated as an emerging pathogen in the respiratory tract of cystic fibrosis patients (<link linkend="ch0038s000000li0039">39</link>). All species of this group are small-colony-forming bacteria (colony size, ≤0.5 mm) that can display variable patterns of hemolysis (alpha, beta, or gamma). Since they can also harbor the Lancefield group A, C, F, or G antigen (or none at all), it is especially important to reliably distinguish them from large-colony-forming (&gt;0.5 mm) beta-hemolytic streptococci of the pyogenic group. Association of certain species with specific isolation sites has been reported, although the associations are not consistently confirmed across studies (<link linkend="ch0038s000000li0040">40</link>). While <emphasis>S. anginosus</emphasis> is frequently found in specimens from the urogenital or gastrointestinal tracts, <emphasis>S. constellatus</emphasis> is commonly isolated from the respiratory tract, and <emphasis>S. intermedius</emphasis> is found in brain and liver abscesses (<link linkend="ch0038s000000li0040">40</link>, <link linkend="ch0038s000000li0041">41</link>).</para>
    </sect1>
    <sect1 id="ch0038s0008">
      <title>S. salivarius Group</title>
      <anchor id="ch0038s000008a0001"/>
      <anchor id="ch0038s000000a0039"/>
      <para id="ch0038s000000p0019">Streptococci that belong to the<emphasis>S. salivarius</emphasis> group include <emphasis>S. salivarius</emphasis> subsp. <emphasis>salivarius</emphasis> and <emphasis>S. vestibularis</emphasis>. They have been isolated primarily from the oral cavity and blood. Another member of this group, <emphasis>S. salivarius</emphasis> subsp. <emphasis>thermophilus</emphasis>, is found only in dairy products. <emphasis>S. salivarius</emphasis> subsp. <emphasis>salivarius</emphasis> has been reported as a cause of bacteremia, endocarditis, and meningitis (sometimes iatrogenic), while <emphasis>S. vestibularis</emphasis> has not been clearly associated with human infection. Isolation of <emphasis>S. salivarius</emphasis> from blood cultures may correlate with neoplasia (<link linkend="ch0038s000000li0042">42</link>).</para>
    </sect1>
    <sect1 id="ch0038s0009">
      <title>S. mutans Group</title>
      <anchor id="ch0038s000009a0001"/>
      <anchor id="ch0038s000000a0040"/>
      <para id="ch0038s000000p0020"><emphasis>S. mutans</emphasis> and <emphasis>S. sobrinus</emphasis> belong to the <emphasis>S. mutans</emphasis> group. They are the most commonly isolated species of the group that originate from human clinical specimens, usually obtained from the oral cavity. <emphasis>S. criceti, S. ratti</emphasis>, and <emphasis>S. downei</emphasis> have occasionally been identified from human sources, while the other streptococcal species of the <emphasis>S. mutans</emphasis> group (<emphasis>S. ferus, S. macacae, S. hyovaginalis</emphasis>, and <emphasis>S. devriesei</emphasis>) have been identified only in animals. <emphasis>S. mutans</emphasis> is the primary etiologic agent of dental caries, and infection is transmissible. Permanent colonization with <emphasis>S. mutans</emphasis> occurs under normal living conditions in the Western world between the second and the end of the third year of life. Molecular analysis of mother and infant isolates reveals that strains are usually acquired from the mother and that the colonization rate of infants depends on the bacterial load of the mother (<link linkend="ch0038s000000li0043">43</link>). Analyses of streptococcal blood culture isolates show that <emphasis>S. mutans</emphasis> is the most frequently isolated species of this group in cases of bacteremia (<link linkend="ch0038s000000li0002">2</link>).</para>
    </sect1>
    <sect1 id="ch0038s0010">
      <title>S. equinus Group (Formerly S. bovis Group)</title>
      <anchor id="ch0038s000010a0001"/>
      <anchor id="ch0038s000000a0041"/>
      <para id="ch0038s000000p0021">The<emphasis>S. equinus</emphasis> group includes <emphasis>S. equinus, S. gallolyticus, S. infantarius, S. lutetiensis</emphasis>, and <emphasis>S. alactolyticus</emphasis> (<link linkend="ch0038s000000a0007">Table 1</link>). Species from this group are frequently encountered in blood cultures of patients with bacteremia, sepsis, and endocarditis. The clinical significance of blood cultures growing streptococci from the <emphasis>S. equinus</emphasis> group lies in the association of <emphasis>S. gallolyticus</emphasis> subsp. <emphasis>gallolyticus</emphasis> with endocarditis, gastrointestinal disorders including colon cancer, and chronic liver disease and of <emphasis>S. gallolyticus</emphasis> subsp. <emphasis>pasteurianus</emphasis> with meningitis in infants (<link linkend="ch0038s000000li0044">44</link>, <link linkend="ch0038s000000li0045">45</link>).</para>
      <anchor id="ch0038s000000a0042"/>
      <beginpage pagenum="434"/>
    </sect1>
    <sect1 id="ch0038s0011">
      <title>Other Streptococci Infrequently Isolated from Human Specimens</title>
      <anchor id="ch0038s000011a0001"/>
      <anchor id="ch0038s000000a0043"/>
      <para id="ch0038s000000p0022">Streptococcal species that are primarily animal pathogens are occasionally isolated from human hosts, in most cases from humans that are in close contact with animals.<emphasis>S. suis, S. porcinus</emphasis>, and <emphasis>S. iniae</emphasis> belong to this category. <emphasis>S. suis</emphasis> is a swine pathogen that has been isolated from cases of human meningitis and bacteremia and can cause outbreaks among humans (<link linkend="ch0038s000000li0046">46</link>). <emphasis>S. suis</emphasis> is encapsulated and appears alpha-hemolytic on sheep blood agar plates, although some strains are beta-hemolytic on horse blood agar. <emphasis>S. suis</emphasis> strains are positive for the Lancefield group R, S, or T antigen, which helps to distinguish them from the phenotypically similar species <emphasis>S. gordonii, S. sanguinis</emphasis>, and <emphasis>S. parasanguinis</emphasis>. Similar to <emphasis>S. suis, S. porcinus</emphasis> (Lancefield groups E, P, U, and V) is primarily a swine pathogen. Beta-hemolytic <emphasis>S. porcinus</emphasis> strains have rarely been isolated from human sources such as peripheral blood, wounds, and the female genital tract (<link linkend="ch0038s000000li0047">47</link>). Molecular studies of <emphasis>S. porcinus</emphasis> isolates from the female genital tract, however, indicate that these isolates belong to a different species, designated <emphasis>S. pseudoporcinus</emphasis> (<link linkend="ch0038s000000li0048">48</link>). <emphasis>S. pseudoporcinus</emphasis> may be more prevalent in the female genital tract than previously assumed, as it possesses the Lancefield group B antigen and may be been misclassified as <emphasis>S. agalactiae</emphasis> (<link linkend="ch0038s000000li0049">49</link>). <emphasis>S. iniae</emphasis> is a fish pathogen that is beta-hemolytic but does not possess any Lancefield group antigens. It has been isolated from soft tissue infections, bacteremia, endocarditis, and meningitis in people who handle fish (<link linkend="ch0038s000000li0050">50</link>). Other streptococcal species associated with aquatic animals and human infections are <emphasis>S. hongkongensis</emphasis> and <emphasis>S. halichoeri</emphasis>. <emphasis>S. hongkongensis</emphasis> is closely related to <emphasis>S. iniae</emphasis> and <emphasis>S. parauberis</emphasis> and can cause invasive infections in humans who handle fish (<link linkend="ch0038s000000li0051">51</link>). <emphasis>S. halichoeri</emphasis> was originally identified in seals but it has recently been found as a cause of human infections (<link linkend="ch0038s000000li0052">52</link>, <link linkend="ch0038s000000li0053">53</link>). Distinct subspecies were identified for human (<emphasis>S. halichoeri</emphasis> subsp. <emphasis>hominis</emphasis>) and seal (<emphasis>S. halichoeri</emphasis> subsp. <emphasis>halichoeri</emphasis>) isolates (<link linkend="ch0038s000000li0052">52</link>, <link linkend="ch0038s000000li0053">53</link>).</para>
      <sect2 id="ch0038s0011s0001">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0038s000011a0002"/>
        <anchor id="ch0038s000000a0044"/>
        <para id="ch0038s000000p0023">Specimens suspected of harboring streptococci should be collected by methods outlined elsewhere (see<ulink url="ch0035#ch0035s0001">chapter 19</ulink>). Since many streptococcal species lose viability fairly quickly, it is best to place swabs in an appropriate moist transport medium and process specimens rapidly. If transport time is below 1 to 2 h, a special transport system is not absolutely necessary. <emphasis>S. pyogenes</emphasis> can be transported on dry swabs; desiccation enhances recovery from mixed cultures by suppression of accompanying microbiota (<link linkend="ch0038s000000li0054">54</link>). Recommendations for collection and storage of swabs from pregnant women to detect <emphasis>S. agalactiae</emphasis> colonization are detailed in the American Society for Microbiology guidelines (<link linkend="ch0038s000000li0025">25</link>). These recommendations are summarized below under “Special Procedures for <emphasis>S. agalactiae</emphasis> Screening.”</para>
      </sect2>
      <sect2 id="ch0038s0011s0002">
        <title>DIRECT EXAMINATION</title>
        <anchor id="ch0038s000011a0003"/>
        <anchor id="ch0038s000000a0045"/>
      </sect2>
    </sect1>
    <sect1 id="ch0038s0012">
      <title>Microscopy</title>
      <anchor id="ch0038s000012a0001"/>
      <anchor id="ch0038s000000a0046"/>
      <para id="ch0038s000000p0024">Microscopic examination shows streptococci as Gram-positive bacteria growing in chains of varying lengths.<emphasis>S. pneumoniae</emphasis> is most often present as Gram-positive diplococci with an elongated appearance, but a reliable distinction of <emphasis>S. pneumoniae</emphasis> from enterococci and other streptococci by morphology is not possible. In blood culture specimens, <emphasis>S. pneumoniae</emphasis> tends to form chains of varying lengths, similar to other streptococci. Microscopic detection of streptococci is clinically helpful, particularly in cerebrospinal fluid (CSF). In abscess- or peritonitis-associated aspirates, tiny, irregular cocci in clumps or chains are suggestive of the <emphasis>S. anginosus</emphasis> group. Interpretation of Gram stain results for specimens from nonsterile body sites is difficult, due to the residential microbiota, which frequently includes streptococci. Thus, for example, throat swabs should not be examined by Gram stain for diagnosis of streptococcal pharyngitis.</para>
    </sect1>
    <sect1 id="ch0038s0013">
      <title>Direct Antigen Detection of S. pyogenes from Throat Specimens</title>
      <anchor id="ch0038s000013a0001"/>
      <anchor id="ch0038s000000a0047"/>
      <para id="ch0038s000000p0025"><emphasis>S. pyogenes</emphasis> is the most common bacterial cause of acute pharyngitis and accounts for 15 to 30% of cases of acute pharyngitis in children and 5 to 10% of cases in adults. A rapid diagnosis allows antibiotic therapy to be initiated promptly to relieve symptoms, avoid sequelae, and reduce transmission. Numerous assays for direct detection of the group A-specific carbohydrate antigen in throat swabs by agglutination methods or immunoassays (enzyme, liposome, or optical), also referred to as rapid antigen assays, are commercially available. Sensitivities of rapid antigen tests are approximately 90% in adults and 80 to 90% in pediatric patients (<link linkend="ch0038s000000li0055">55</link>). Although these tests provide rapid results and allow early treatment decisions, throat culture remains the reference method. Negative rapid antigen test results should therefore be confirmed by culture in children and adolescents when typical clinical signs are present. In adults, the confirmation of negative rapid antigen test results has not been regarded as necessary, unless clinical suspicion is high and the physician wishes to ensure maximal sensitivity with conventional throat culture (<link linkend="ch0038s000000li0056">56</link>). The specificity of rapid antigen test results is generally high, though false-positive results are seen from patients previously diagnosed with and/or treated for <emphasis>S. pyogenes</emphasis> (<link linkend="ch0038s000000li0057">57</link>). Moreover, the low positive predictive value of rapid group A antigen tests in the adult population frequently results in prescribing unnecessary antimicrobial therapy.</para>
    </sect1>
    <sect1 id="ch0038s0014">
      <title>Streptococcal Antigen Detection</title>
      <anchor id="ch0038s000014a0001"/>
      <anchor id="ch0038s000000a0048"/>
      <para id="ch0038s000000p0026">Commercially available antigen detection tests for the diagnosis of pathogenic microorganisms in CSF samples include reagents for the detection of<emphasis>S. agalactiae</emphasis> and <emphasis>S. pneumoniae</emphasis>. These tests have also been used on positive blood culture specimens. The tests are not recommended for routine use, because the results should not be used to change decisions about empiric therapy based on clinical and laboratory criteria. It has also been shown that the sensitivity of direct antigen detection in CSF is low (&lt;30%) and offers no advantage over a conventional centrifuge Gram stain (<link linkend="ch0038s000000li0058">58</link>). However, use of the BinaxNOW <emphasis>S. pneumoniae</emphasis> antigen test on CSF samples works well (<link linkend="ch0038s000000li0059">59</link>) and is an application for which the test has received FDA clearance.</para>
      <para id="ch0038s000000p0027">Although the BinaxNOW antigen test is also approved for detection of<emphasis>S. pneumoniae</emphasis> C-polysaccharide antigen in urine samples, it has significant limitations, including low sensitivity (50 to 80%) and specificity issues, as it can remain positive for 1 to 6 months after pneumococcal infection and is positive in cases of <emphasis>S. pneumoniae</emphasis> carriage without infection, as is often observed among children (<link linkend="ch0038s000000li0060">60</link>–<link linkend="ch0038s000000li0062">62</link>).</para>
    </sect1>
    <sect1 id="ch0038s0015">
      <title>Nucleic Acid Detection Techniques</title>
      <anchor id="ch0038s000015a0001"/>
      <anchor id="ch0038s000000a0049"/>
      <anchor id="ch0038s000000a0050"/>
      <sect2 id="ch0038s0015s0001">
        <title>S. pyogenes</title>
        <anchor id="ch0038s000015a0002"/>
        <anchor id="ch0038s000000a0051"/>
        <para id="ch0038s000000p0028">Several commercial amplification methods for the direct detection of<emphasis>S. pyogenes</emphasis> have received FDA clearance. The tests allow detection of <emphasis>S. pyogenes</emphasis> in throat swabs and provide results in less than an hour. Clinical studies report sensitivities above 90%, exceeding the values of rapid antigens tests (<link linkend="ch0038s000000li0063">63</link>, <link linkend="ch0038s000000li0064">64</link>). The Xpert Xpress Strep A (Cepheid, Sunnyvale, CA) and the Cobas Strep A (Roche Diagnostics, Basel, Switzerland) test results do not need confirmation by culture as detailed by the manufacturer, while other assays may require backup culture for negative specimens.</para>
      </sect2>
      <sect2 id="ch0038s0015s0002">
        <title>S. agalactiae</title>
        <anchor id="ch0038s000015a0003"/>
        <anchor id="ch0038s000000a0052"/>
        <para id="ch0038s000000p0029">Several nucleic acid amplification tests (NAATs) for the detection of<emphasis>S. agalactiae</emphasis> colonization in pregnant women have received FDA clearance, with some performed following broth enrichment and other designed for testing directly from specimens. While the costs of nucleic acid-based tests are higher than for selective culture, these tests were designed to provide results within a short time frame and to be able to assess vaginal/rectal colonization status at the time of delivery. Although NAATs performed at the time of delivery provide rapid results, the current ASM guidelines do not recommend performing NAATs directly from specimen without broth culture enrichment (<link linkend="ch0038s000000li0025">25</link>). Enrichment procedures considerably increase the sensitivity of NAAT to detect <emphasis>S. agalactiae</emphasis> colonization.</para>
      </sect2>
      <sect2 id="ch0038s0015s0003">
        <title>S. pneumoniae</title>
        <anchor id="ch0038s000015a0004"/>
        <anchor id="ch0038s000000a0053"/>
        <para id="ch0038s000000p0030">Several laboratory-developed NAATs have been developed for the identification of<emphasis>S. pneumoniae</emphasis> from culture isolates and have also been successfully used with culture-independent specimens, such as nasopharyngeal swabs. Tests are based on the detection of <emphasis>lytA</emphasis> (encoding autolysin), <emphasis>piaB</emphasis> (permease gene of the <emphasis>pia</emphasis> ABC transporter) (<link linkend="ch0038s000000li0065">65</link>, <link linkend="ch0038s000000li0066">66</link>), and SP2020 (putative transcriptional regulator gene) (<link linkend="ch0038s000000li0067">67</link>). So far, none of these assays are commercially available, so they have to be established as laboratory-developed tests. <emphasis>S. pneumoniae</emphasis>-specific primers are included in commercial but not FDA-cleared multiplex arrays for the detection of pathogens in respiratory samples, such as the Fast-Track Diagnostics multiplex respiratory panel and the TaqMan array card (<link linkend="ch0038s000000li0068">68</link>). <emphasis>S. pneumoniae</emphasis> was detected more frequently by the TaqMan array card than by the Fast-Track Diagnostics assay when parallel testing was conducted with a set of clinical specimens (<link linkend="ch0038s000000li0068">68</link>). FDA-cleared multiplex lower respiratory panels are available, with some providing semiquantitative results to assist with the determination of clinical significance of the detected organisms (<link linkend="ch0038s000000li0069">69</link>). In addition, the FDA-cleared FilmArray meningitis/encephalitis (BioFire Diagnostics, LLC, Salt Lake City, UT) panel detects <emphasis>S. pneumoniae</emphasis> nucleic acids from CSF specimens. This multiplex assay detects numerous viral and bacterial pathogens in CSF, but false-positive <emphasis>S. pneumoniae</emphasis> results occur at a considerable frequency (<link linkend="ch0038s000000li0070">70</link>). There are a number of FDA-cleared direct identification systems for streptococci from positive blood cultures. Accurate identification of the majority of on-panel streptococci from monomicrobial cultures, including <emphasis>S. agalactiae, S. pyogenes</emphasis>, and <emphasis>S. anginosus</emphasis> group, has been reported; however, incorrect identifications between <emphasis>S. pneumoniae</emphasis> and the <emphasis>S. mitis</emphasis> group occur (<link linkend="ch0038s000000li0071">71</link>, <link linkend="ch0038s000000li0072">72</link>).</para>
        <para id="ch0038s000000p0031">A nucleic acid probe for the confirmation of cultured isolates as<emphasis>S. pneumoniae</emphasis> is commercially available (AccuProbe; Hologic Inc., Marlborough, MA). This test is not routinely performed for standard identification procedures but can aid in the identification of atypical <emphasis>S. pneumoniae</emphasis> isolates with unusual patterns of bile solubility and optochin susceptibility, although it does not distinguish <emphasis>S. pseudopneumoniae</emphasis> from <emphasis>S. pneumoniae</emphasis> (<link linkend="ch0038s000000li0073">73</link>).</para>
      </sect2>
      <sect2 id="ch0038s0015s0004">
        <title>ISOLATION PROCEDURES</title>
        <anchor id="ch0038s000015a0005"/>
        <anchor id="ch0038s000000a0054"/>
      </sect2>
    </sect1>
    <sect1 id="ch0038s0016">
      <title>General Procedures</title>
      <anchor id="ch0038s000016a0001"/>
      <anchor id="ch0038s000000a0055"/>
      <para id="ch0038s000000p0032">Streptococci are usually grown on blood agar media, because the assessment of the hemolytic reaction is important for identification. Growth of streptococci is often enhanced in the presence of an exogenous catalase source. Streptococcal species with low or absent hydrogen peroxide production, such as<emphasis>S. agalactiae</emphasis>, can be grown on other commonly used nonselective media without blood. Agar media selective for Gram-positive bacteria (e.g., phenylethyl alcohol-containing agar or Columbia agar with colistin and nalidixic acid) support the growth of streptococci. The optimal incubation temperature range for most streptococcal species lies between 35 and 37°C. Supplemental carbon dioxide (5% CO<subscript>2</subscript>) or anaerobic conditions enhance the growth of many streptococcal species, since streptococci are facultative anaerobes. Although some streptococci grow well in ambient air, incubation in 5% CO<subscript>2</subscript> is recommended for the culture of <emphasis>S. pneumoniae</emphasis> and other streptococcal species of the viridans group.</para>
    </sect1>
    <sect1 id="ch0038s0017">
      <title>Special Procedures for S. pyogenes Throat Cultures</title>
      <anchor id="ch0038s000017a0001"/>
      <anchor id="ch0038s000000a0056"/>
      <para id="ch0038s000000p0033">A properly performed and interpreted throat culture on a 5% sheep blood agar with Trypticase soy base incubated in air remains the gold standard for the diagnosis of<emphasis>S. pyogenes</emphasis> in acute pharyngitis (<link linkend="ch0038s000000li0074">74</link>). The isolation of only a few colonies of <emphasis>S. pyogenes</emphasis> does not allow the differentiation between a carrier and an acutely infected individual and may reflect inadequate specimen collection (<link linkend="ch0038s000000li0075">75</link>). Lack of hemolysis, overgrowth, and production of toxic bacterial metabolites by normal upper respiratory tract microbiota or depletion of substrates may lead to false-negative results or delays caused by labor-intensive reisolation steps. To enhance <emphasis>S. pyogenes</emphasis> isolation, numerous studies analyzed incubation conditions in an anaerobic or CO<subscript>2</subscript>-enriched atmosphere as well as different media selective for beta-hemolytic streptococci (<link linkend="ch0038s000000li0076">76</link>). Due to cost restraints and an uncertain benefit, these additional efforts are not generally recommended for <emphasis>S. pyogenes</emphasis> but may increase the yield of other beta-hemolytic streptococci. After 18 to 24 h of incubation, culture plates should be examined for growth of beta-hemolytic colonies. Negative cultures should be reexamined after an additional 24-h incubation period. Presumptive identification of <emphasis>S. pyogenes</emphasis> can be achieved by susceptibility to bacitracin or testing for pyrrolidonyl aminopeptidase (PYR) activity. Other beta-hemolytic streptococci are occasionally positive in one of these tests but not in both. Definitive identification includes the demonstration of the Lancefield group A antigen by immunoassay or MALDI-TOF MS analysis. Although other species may rarely possess the group A antigen (<link linkend="ch0038s000000a0012">Table 2</link>), they lack PYR activity (<link linkend="ch0038s000000li0002">2</link>). CHROMagar plates have been developed for the detection of <emphasis>S. pyogenes</emphasis> from throat specimens. The advantage of the CHROMagar plate is the ability to select <emphasis>S. pyogenes</emphasis> from among other members of the oral flora due to colony color (<link linkend="ch0038s000000li0077">77</link>).</para>
    </sect1>
    <sect1 id="ch0038s0018">
      <title>Special Procedures for S. agalactiae Screening</title>
      <anchor id="ch0038s000018a0001"/>
      <anchor id="ch0038s000000a0057"/>
      <para id="ch0038s000000p0034">Early-onset neonatal group B streptococcal (<emphasis>S. agalactiae</emphasis>) infections can be prevented by the administration of intrapartum antibiotic prophylaxis (<link linkend="ch0038s000000li0023">23</link>). Appropriate prophylaxis requires reliable detection of colonization with <emphasis>S. agalactiae</emphasis> before delivery. Screening should be performed at 36 0/7 to 37 6/7 weeks of gestation. A lower vaginal and a rectal swab (i.e., a swab inserted through the anal sphincter) is collected with one flocked swab and immediately placed in appropriate transport medium (Amies or Stuart’s medium with or without charcoal or ESwab [Copan Diagnostics, Murrieta, CA]; see <ulink url="ch0035#ch0035s0001">chapter 19</ulink>) and transported to the laboratory within 24 h (<link linkend="ch0038s000000li0025">25</link>). Swabs should be cultured in selective enrichment broth medium for 18 to 24 h at 35 to 37°C in ambient air or 5% CO<subscript>2</subscript> and subsequently plated on tryptic soy agar or Columbia agar with 5% sheep blood, Columbia agar with colistin and nalidixic acid (CNA), or some differential or chromogenic media. Selective enrichment broth medium is commercially available but can also be prepared by supplementation of Todd-Hewitt broth with either nalidixic acid (15 μg/ml) and colistin (10 μg/ml) or with nalidixic acid (15 μg/ml) and gentamicin (8 μg/ml). Differential enrichment broths are available and enable more rapid reporting of <emphasis>S. agalactiae</emphasis> detection directly from broth; however, nonhemolytic strains are not detected, so negative broths require further testing. Agar plates should be checked for typical colonies (narrow zone of hemolysis on blood-containing agar) of <emphasis>S. agalactiae</emphasis> after 24 and 48 h of incubation at 35 to 37°C. Identification of <emphasis>S. agalactiae</emphasis> is then achieved by standard techniques as described below. Some differential media (e.g., Granada medium) utilize <emphasis>S. agalactiae</emphasis>’s red-orange pigment for detection, while other chromogenic media are pigment production independent. Nonhemolytic strains are not detected by pigment-dependent selective media. NAAT-based detection of <emphasis>S. agalactiae</emphasis> following overnight enrichment broth increases sensitivity and reduces detection time compared to conventional selective culture (<link linkend="ch0038s000000li0078">78</link>). It is recommended as an alternative screening method by the ASM guidelines (<link linkend="ch0038s000000li0025">25</link>).</para>
      <anchor id="ch0038s000000a0058"/>
      <beginpage pagenum="436"/>
      <sect2 id="ch0038s0018s0001">
        <title>IDENTIFICATION</title>
        <anchor id="ch0038s000018a0002"/>
        <anchor id="ch0038s000000a0059"/>
      </sect2>
    </sect1>
    <sect1 id="ch0038s0019">
      <title>Description of Colonies</title>
      <anchor id="ch0038s000019a0001"/>
      <anchor id="ch0038s000000a0060"/>
      <para id="ch0038s000000p0035">Colonies of streptococci usually appear gray or almost white with moist or glistening features. Dry colonies are rarely encountered. Colony size varies between the different beta-hemolytic species and helps to distinguish groups of streptococci. Beta-hemolytic streptococci of the pyogenic group (<emphasis>S. pyogenes, S. agalactiae</emphasis>, and <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis>) form colonies of &gt;0.5 mm after 24 h of incubation, in contrast to beta-hemolytic strains of the <emphasis>S. anginosus</emphasis> group, which form pinpoint colonies of &lt;0.5 mm after the same incubation time (<anchor id="ch0038s000000a0061"/><link linkend="ch0038s000000a0068">Fig. 1</link>). Members of the <emphasis>S. anginosus</emphasis> group emit a distinct odor resembling butterscotch or caramel, presumably due to the production of diacetyl by the species belonging to this group. Among the beta-hemolytic species of the pyogenic group, <emphasis>S. agalactiae</emphasis> produces the largest colonies with a relatively small zone of hemolysis. Nonhemolytic <emphasis>S. agalactiae</emphasis> strains do occur, and the colonies resemble those of enterococci.</para>
      <para id="ch0038s000000p0036">Within the group of alpha-hemolytic streptococci,<emphasis>S. pneumoniae</emphasis> has a colony morphology that helps to distinguish pneumococcal isolates from other streptococci of the viridans group. Due to the production of capsular polysaccharide, colonies glisten and appear moist. Colonies may be large and mucoid if large amounts of capsular polysaccharide are made, a feature often encountered in serotype 3 strains. This phenotype is usually typical for <emphasis>S. pneumoniae</emphasis> but can also occasionally be observed in <emphasis>S. pyogenes</emphasis>. Another characteristic feature of <emphasis>S. pneumoniae</emphasis> is the central navel-like depression of the colonies that is caused by the pneumococcal autolysin. Other viridans group streptococci lack this feature and have a dome-like appearance; however, up to 20% of <emphasis>S. pneumoniae</emphasis> strains display a phenotype that is indistinguishable from viridans group streptococci (<link linkend="ch0038s000000li0079">79</link>). Nonhemolytic gray colonies are typical for species of the <emphasis>S. equinus</emphasis> and <emphasis>S. salivarius</emphasis> groups. Typical streptococcal colony morphologies are presented in <link linkend="ch0038s000000a0068">Fig. 1</link>.</para>
    </sect1>
    <sect1 id="ch0038s0020">
      <title>MALDI-TOF MS and Phenotypic Tests</title>
      <anchor id="ch0038s000020a0001"/>
      <anchor id="ch0038s000000a0062"/>
      <para id="ch0038s000000p0037">A number of streptococcal identification products incorporating batteries of physiologic tests are commercially available (see<ulink url="ch0021#ch0021s0001">chapter 6</ulink>). In general, these products perform well with commonly isolated pathogenic streptococci but may lack accuracy for identifying streptococci of the viridans group. For the bulk of pathogenic streptococci isolated in clinical laboratories (e.g., <emphasis>S. pyogenes, S. agalactiae</emphasis>, and <emphasis>S. pneumoniae</emphasis>), serologic or presumptive physiologic tests (as described below) still offer an acceptable alternative to commercially available identification systems.</para>
    </sect1>
    <sect1 id="ch0038s0021">
      <title>MALDI-TOF MS</title>
      <anchor id="ch0038s000021a0001"/>
      <anchor id="ch0038s000000a0063"/>
      <para id="ch0038s000000p0038">Although MALDI-TOF MS-based bacterial identification has become the predominant identification method for most bacterial species, the method has significant limitations for streptococci. Currently, two commercial systems are available: the MALDI Biotyper CA system (Bruker, Billerica, MA) and the Vitek MS instrument (bioMérieux, Marcy-l’Étoile, France). Both systems generally provide accurate identification of<emphasis>S. pyogenes, S. agalactiae</emphasis>, and <emphasis>S. pneumoniae</emphasis>, but considerable difficulties exist for the identification of <emphasis>S. dysgalactiae</emphasis> and viridans group streptococci other than <emphasis>S. pneumoniae</emphasis> (<link linkend="ch0038s000000li0080">80</link>). Databases are continually updated in order to address these challenges. Currently, there remains a potential for misidentifications between <emphasis>S. pyogenes, S. dysgalactiae</emphasis>, and <emphasis>S. canis</emphasis> (<link linkend="ch0038s000000li0081">81</link>). Database updates of the MALDI Biotyper CA system improved the identification of streptococci from the <emphasis>S. mitis</emphasis> group, especially for <emphasis>S. pneumoniae</emphasis> (<link linkend="ch0038s000000li0082">82</link>). For the VITEK MS instrument, a better identification of viridans group streptococci was reported; however, <emphasis>S</emphasis>. <emphasis>pneumoniae</emphasis> isolates may be misidentified as <emphasis>S. oralis/S. mitis</emphasis>, and therefore, isolates should be confirmed (<link linkend="ch0038s000000li0083">83</link>). For both instruments, the reliable species identification of viridans group streptococci other than <emphasis>S. pneumoniae</emphasis> remains problematic for the <emphasis>S. mitis, S. anginosus</emphasis>, and <emphasis>S. equinus</emphasis> groups. Due to potential misidentifications between <emphasis>S</emphasis>. <emphasis>pyogenes</emphasis> and <emphasis>S. dysgalactiae</emphasis> or <emphasis>S. canis</emphasis> and <emphasis>S. pneumoniae</emphasis> with <emphasis>S. oralis</emphasis>/<emphasis>S. mitis</emphasis>, laboratories may continue to confirm identifications with phenotypic tests, such as PYR and bile solubility, respectively.</para>
    </sect1>
    <sect1 id="ch0038s0022">
      <title>Phenotypic Tests for Identification of Beta-Hemolytic Streptococci</title>
      <anchor id="ch0038s000022a0001"/>
      <anchor id="ch0038s000000a0064"/>
      <sect2 id="ch0038s0022s0001">
        <title>Lancefield Antigen Immunoassays</title>
        <anchor id="ch0038s000022a0002"/>
        <anchor id="ch0038s000000a0065"/>
        <para id="ch0038s000000p0039">Although MALDI-TOF MS has largely replaced the need for Lancefield grouping, commercially available Lancefield antigen grouping sera are available and are primarily used for beta-hemolytic streptococci. The presence of the Lancefield group B antigen in beta-hemolytic isolates from human clinical specimens correlates with the species<emphasis>S. agalactiae</emphasis>, but reactivity of group B antigen tests with the rare species <emphasis>S. pseudoporcinus</emphasis> and <emphasis>S. halichoeri</emphasis> has been reported (<link linkend="ch0038s000000li0052">52</link>, <link linkend="ch0038s000000li0053">53</link>), as well as a positive CAMP test reaction. A positive PYR reaction and failure to hydrolyze hippurate help to differentiate <emphasis>S. porcinus</emphasis> and <emphasis>S. pseudoporcinus</emphasis> from <emphasis>S. agalactiae</emphasis>. Detection of the Lancefield group F antigen in small-colony-forming streptococci from human clinical material allows a fairly reliable identification of a strain as a member of the <emphasis>S. anginosus</emphasis> group. The presence of Lancefield group A, C, or G antigens necessitates further testing (<link linkend="ch0038s000000a0012">Table 2</link>). Beta-hemolytic streptococcal strains not reacting with any of the Lancefield antisera are rare and should be further identified by phenotypic tests or nucleic acid detection techniques.</para>
        <anchor id="ch0038s000000a0066"/>
        <beginpage pagenum="437"/>
        <figure id="ch0038s000000f0001"><title><anchor id="ch0038s000000a0067"/><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0038s000000a0068"/><link linkend="ch0038s000000a0061">FIGURE 1</link></phrase></emphasis> Colony morphology of selected streptococci. (A) <emphasis>S. pyogenes</emphasis> strain ATCC 12344. (B) Clinical isolate of <emphasis>S. agalactiae</emphasis>. (C) Clinical isolate of <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> (Lancefield group G). (D) Mixed culture of <emphasis>S. anginosus</emphasis> (ATCC 12395) (open arrow) and clinical isolate of <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> (closed arrow) (note the difference in colony size). (E) Clinical isolate of <emphasis>S. pneumoniae</emphasis> (note the central depression of the colonies). (F) Clinical isolate of <emphasis>S. pneumoniae</emphasis> (note the mucoid appearance of colonies).
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0038f03.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0038s0022s0002">
        <title>PYR Test</title>
        <anchor id="ch0038s000022a0003"/>
        <anchor id="ch0038s000000a0069"/>
        <para id="ch0038s000000p0040">The presence of the enzyme PYR is often tested to distinguish<emphasis>S. pyogenes</emphasis> from other beta-hemolytic streptococci. Hydrolysis of <phrase role="small">L</phrase>-pyrrolidonyl-β-naphthylamide by the enzyme to β-naphthylamide produces a red color with the addition of cinnamaldehyde reagent. The beta-hemolytic species <emphasis>S. iniae, S. porcinus</emphasis>, and <emphasis>S. pseudoporcinus</emphasis> can be PYR positive but are only rarely identified in human clinical specimens. <emphasis>S. iniae</emphasis> isolates resemble <emphasis>S. pyogenes</emphasis> strains, but beta-hemolysis of the species can be observed only around agar stabs or under anaerobic culture conditions. The failure of <emphasis>S. iniae</emphasis> to react with Lancefield group antisera is important to notice, since it is rare among beta-hemolytic streptococci. It is important to distinguish <emphasis>Streptococcus</emphasis> from <emphasis>Enterococcus</emphasis> prior to PYR testing, and strains of other related genera may be PYR positive (including the genera <emphasis>Abiotrophia, Aerococcus, Gemella</emphasis>, and <emphasis>Lactococcus</emphasis>). However, PYR-positive beta-hemolytic enterococcal isolates typically present with a different colonial morphology (smaller zone of beta-hemolysis and bigger colony size) and, when these are combined with other phenotypic characteristics (see <ulink url="ch0039#ch0039s0001">chapter 23</ulink>), may be distinguished from streptococci. To avoid false-positive reactions caused by other PYR-positive bacterial species (for example, staphylococci), the test should be performed only on pure cultures.</para>
      </sect2>
      <sect2 id="ch0038s0022s0003">
        <title>Bacitracin Susceptibility</title>
        <anchor id="ch0038s000022a0004"/>
        <anchor id="ch0038s000000a0070"/>
        <para id="ch0038s000000p0041">With rare exceptions,<emphasis>S. pyogenes</emphasis> displays bacitracin susceptibility, in contrast to other human beta-hemolytic streptococci. Together with Lancefield antigen determination, it can be used for the identification of <emphasis>S. pyogenes</emphasis>, since beta-hemolytic strains of other streptococcal species that may contain the group A antigen are bacitracin resistant. The test can also be used to distinguish <emphasis>S. pyogenes</emphasis> from other PYR-positive beta-hemolytic streptococci (<emphasis>S. iniae</emphasis> and <emphasis>S. porcinus</emphasis>). A bacitracin disk (0.04 U) is applied to a sheep blood agar plate that has been heavily inoculated with three to four colonies of a pure culture of the strain to be tested. It is important to perform the test from a subculture on sheep blood agar, since placement of bacitracin disks on primary plates is not sensitive enough. After overnight incubation at 35°C in 5% CO<subscript>2</subscript>, any zone of inhibition around the disk is interpreted as indicating susceptibility. Importantly, bacitracin-resistant <emphasis>S. pyogenes</emphasis> isolates have been reported, and clusters of bacitracin-resistant strains were observed in several European countries (<link linkend="ch0038s000000li0084">84</link>, <link linkend="ch0038s000000li0085">85</link>).</para>
        <anchor id="ch0038s000000a0071"/>
        <beginpage pagenum="438"/>
      </sect2>
      <sect2 id="ch0038s0022s0004">
        <title>VP Test</title>
        <anchor id="ch0038s000022a0005"/>
        <anchor id="ch0038s000000a0072"/>
        <para id="ch0038s000000p0042">The Voges-Proskauer (VP) test detects the formation of acetoin from glucose fermentation. It is performed on streptococci as a modification of the classical VP reaction that is used for the differentiation of enteric bacteria. Small-colony-forming beta-hemolytic streptococci of the<emphasis>S. anginosus</emphasis> group that are VP positive may be distinguished from large-colony-forming beta-hemolytic streptococci harboring identical Lancefield antigens (A, C, or G). Streptococci of the <emphasis>S. mitis</emphasis> group are VP negative. For the modified VP reaction as described by Facklam, the culture growth of an entire agar plate is used to inoculate 2 ml of VP broth and incubated at 35°C for 6 h. Following the addition of 5% α-naphthol and 40% KOH, the tube is shaken vigorously for a few seconds and incubated at room temperature for 30 min. A positive test yields a pink-red color that results from the reaction of diacetyl with guanidine.</para>
      </sect2>
      <sect2 id="ch0038s0022s0005">
        <title>β-Glucuronidase Test</title>
        <anchor id="ch0038s000022a0006"/>
        <anchor id="ch0038s000000a0073"/>
        <para id="ch0038s000000p0043">Detection of β-glucuronidase activity distinguishes<emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> strains containing Lancefield group antigen C or G from β-glucuronidase-negative, small-colony-forming streptococci of the <emphasis>S. anginosus</emphasis> group with the same Lancefield group antigens. Rapid methods for the β-glucuronidase test are commercially available. Alternatively, a rapid fluorogenic assay is described elsewhere in this <emphasis>Manual</emphasis>.</para>
      </sect2>
      <sect2 id="ch0038s0022s0006">
        <title>CAMP Test</title>
        <anchor id="ch0038s000022a0007"/>
        <anchor id="ch0038s000000a0074"/>
        <para id="ch0038s000000p0044">The CAMP factor reaction was first described in 1944 by Christie, Atkins, and Munch-Petersen and refers to the synergistic lysis of erythrocytes by the hemolysin of<emphasis>Staphylococcus aureus</emphasis> and the extracellular CAMP factor of <emphasis>S. agalactiae</emphasis>. The gene (<emphasis>cfb</emphasis>) and its expression can be demonstrated in the vast majority (&gt;98%) of <emphasis>S. agalactiae</emphasis> isolates, but CAMP-negative mutants do occur. The strain to be tested and an <emphasis>S. aureus</emphasis> strain (ATCC 25923) are streaked onto a sheep blood agar plate at a 90° angle. Plates are incubated in ambient air overnight at 36 ± 1°C. A positive reaction can be detected by the presence of a triangular zone of enhanced beta-hemolysis in the diffusion zone of the beta-hemolysin of <emphasis>S. aureus</emphasis> and the CAMP factor (<anchor id="ch0038s000000a0075"/><link linkend="ch0038s000000a0077">Fig. 2</link>). CAMP factor-positive strains can also be detected by a method using β-lysin-containing disks (Remel Inc., Lenexa, KS) or by a rapid CAMP factor spot method (<link linkend="ch0038s000000li0086">86</link>). Despite the fact that close homologs of the CAMP factor gene are present in many <emphasis>S. pyogenes</emphasis> strains, most beta-hemolytic streptococci other than <emphasis>S. agalactiae</emphasis> are negative in the above-described CAMP factor test, except for the rare human isolates of <emphasis>S. iniae, S. porcinus</emphasis>, and <emphasis>S. pseudoporcinus</emphasis>. Several Gram-positive rods, including corynebacteria and <emphasis>Listeria monocytogenes</emphasis> strains, may also be CAMP factor positive.</para>
        <figure id="ch0038s000000f0002"><title><anchor id="ch0038s000000a0076"/><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0038s000000a0077"/><link linkend="ch0038s000000a0075">FIGURE 2</link></phrase></emphasis> CAMP factor test. Arrowhead-shaped zone of hemolysis in the zone of the <emphasis>S. aureus</emphasis> beta-hemolysin. (A) Clinical isolate of a weakly beta-hemolytic <emphasis>S. agalactiae</emphasis> strain. (B) Beta-hemolytic <emphasis>S. agalactiae</emphasis> strain O90R. (C) Nonhemolytic <emphasis>S. agalactiae</emphasis> strain R268.
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0038f02.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0038s0022s0007">
        <title>Hippurate Hydrolysis Test</title>
        <anchor id="ch0038s000022a0008"/>
        <anchor id="ch0038s000000a0078"/>
        <para id="ch0038s000000p0045">The ability to hydrolyze hippurate is an alternative test for the presumptive identification of<emphasis>S. agalactiae</emphasis>. A rapid version of the test as it is used for <emphasis>Campylobacter</emphasis> is described elsewhere in this <emphasis>Manual</emphasis>. Streptococci other than <emphasis>S. agalactiae</emphasis> may also be hippurate hydrolysis positive, especially viridans group streptococci.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0038s0023">
      <title>Physiological Traits of S. pneumoniae and Viridans Group Streptococci</title>
      <anchor id="ch0038s000023a0001"/>
      <anchor id="ch0038s000000a0079"/>
      <para id="ch0038s000000p0046">The correct species identification of viridans group streptococci other than<emphasis>S. pneumoniae</emphasis> is challenging. Recent taxonomic changes and identification of novel streptococcal species have further complicated matters. The viridans group includes alpha-hemolytic, nonhemolytic (<emphasis>S. salivarius</emphasis> group and <emphasis>S. equinus</emphasis> group), and beta-hemolytic (<emphasis>S. anginosus</emphasis> group) streptococcal strains. All of the viridans group streptococci are leucine aminopeptidase positive and PYR negative. Conventional microbiologic tests are limited with respect to species identification but are helpful in placing isolates in the correct streptococcal groups (<anchor id="ch0038s000000a0080"/><link linkend="ch0038s000000a0082">Table 3</link>). Importantly, most clinical laboratories must strive for group, instead of species, classifications with current phenotypic test panels.</para>
      <para id="ch0038s000000p0047">The API tests (bioMérieux) offer species identification of viridans group streptococci. While many species from this group are identified with acceptable accuracy, several species have not been included in the database, and these will get incorrect species assignments. Evaluation studies performed under routine clinical conditions appear to yield less favorable results (<link linkend="ch0038s000000li0087">87</link>). Currently, fully automated systems such as the VITEK 2 (bioMérieux) or MALDI-TOF MS instruments are used for streptococcal identification. Evaluations of the VITEK 2 phenotypic identification system showed that streptococcal group assignment for 75% of isolates was concordant with 16S rRNA gene sequencing data (<link linkend="ch0038s000000li0088">88</link>). In another study, correct identification at the species level was accomplished in only 55% of the tested isolates (<link linkend="ch0038s000000li0089">89</link>). Similarly, MALDI-TOF MS technology, which is discussed above, has problems with the correct species identification of streptococci from the viridans group. In conclusion, phenotypic and automated species identification of viridans group streptococci remains challenging, and acceptable results can currently be achieved only at the group level.</para>
      <anchor id="ch0038s000000a0081"/>
      <beginpage pagenum="439"/>
      <table id="ch0038s000000t0003"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0038s000000a0082"/><link linkend="ch0038s000000a0080">TABLE 3</link></phrase></emphasis> Phenotypic characteristics of major streptococcal groups<superscript><emphasis><anchor id="ch0038s000000a0083"/><link linkend="ch0038s000000a0089">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="7">
          <tbody>
            <row>
              <entry>Streptococcal group</entry>
              <entry><phrase role="center">Arginine hydrolysis</phrase>
              </entry>
              <entry><phrase role="center">Esculin</phrase>
              </entry>
              <entry><phrase role="center">Mannitol</phrase>
              </entry>
              <entry><phrase role="center">Sorbitol</phrase>
              </entry>
              <entry><phrase role="center">Urea hydrolysis</phrase>
              </entry>
              <entry><phrase role="center">VP</phrase>
              </entry>
            </row>
            <row>
              <entry><emphasis>S. miti</emphasis>s<superscript><emphasis><anchor id="ch0038s000000a0084"/><link linkend="ch0038s000000a0090">b</link></emphasis></superscript></entry>
              <entry><phrase role="center">V</phrase>
              </entry>
              <entry><phrase role="center">V</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">V</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
            <row>
              <entry><emphasis>S. anginosus</emphasis>
                <superscript>
                  <emphasis>
                    <anchor id="ch0038s000000a0085"/>
                    <link linkend="ch0038s000000a0091">c</link>
                  </emphasis>
                </superscript>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
            </row>
            <row>
              <entry><emphasis>S. mutans</emphasis>
                <superscript>
                  <emphasis>
                    <anchor id="ch0038s000000a0086"/>
                    <link linkend="ch0038s000000a0092">d</link>
                  </emphasis>
                </superscript>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
            </row>
            <row>
              <entry><emphasis>S. salivarius</emphasis>
                <superscript>
                  <emphasis>
                    <anchor id="ch0038s000000a0087"/>
                    <link linkend="ch0038s000000a0093">e</link>
                  </emphasis>
                </superscript>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">V</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">V</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
            </row>
            <row>
              <entry><emphasis>S. equinus</emphasis>
                <superscript>
                  <emphasis>
                    <anchor id="ch0038s000000a0088"/>
                    <link linkend="ch0038s000000a0094">f</link>
                  </emphasis>
                </superscript>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">V</phrase>
              </entry>
              <entry><phrase role="center">V</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0089"/><link linkend="ch0038s000000a0083">a</link></emphasis></superscript>+, positive; −, negative; V, variable.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0090"/><link linkend="ch0038s000000a0084">b</link></emphasis></superscript>This group comprises the species <emphasis>S. australis, S. cristatus, S. gordonii, S. infantis, S. lactarius, S. massiliensis, S. mitis, S. oralis</emphasis> subsp<emphasis>. dentisani, S. oralis</emphasis> subsp<emphasis>. oralis, S. oralis</emphasis> subsp<emphasis>. tigurinus, S. parasanguinis, S. peroris, S. pneumoniae, S. pseudopneumoniae, S. rubneri, S. sanguinis, S. sinensis, S. parasanguinis, S. gordonii</emphasis>, and <emphasis>S. cristatus</emphasis>, which are arginine hydrolysis positive. Other species from the <emphasis>S. mitis</emphasis> group are arginine hydrolysis negative.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0091"/><link linkend="ch0038s000000a0085">c</link></emphasis></superscript><emphasis>S. anginosus, S. constellatus</emphasis>, and <emphasis>S. intermedius</emphasis> belong to the <emphasis>S. anginosus</emphasis> group.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0092"/><link linkend="ch0038s000000a0086">d</link></emphasis></superscript>The <emphasis>S. mutans</emphasis> group includes S<emphasis>. mutans, S. sobrinus</emphasis>, and the following species, which are rarely isolated from humans: <emphasis>S. criceti, S. ratti</emphasis>, and <emphasis>S. downei</emphasis>.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0093"/><link linkend="ch0038s000000a0087">e</link></emphasis></superscript>The <emphasis>S. salivarius</emphasis> group contains <emphasis>S. salivarius</emphasis> subsp<emphasis>. salivarius, S. vestibularis</emphasis>, and <emphasis>S. salivarius</emphasis> subsp<emphasis>. thermophilus</emphasis>. <emphasis>S. salivarius</emphasis> is variable for urea hydrolysis, <emphasis>S. vestibularis</emphasis> is positive, and <emphasis>S. salivarius</emphasis> subsp<emphasis>. thermophilus</emphasis> is negative for urea hydrolysis.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0094"/><link linkend="ch0038s000000a0088">f</link></emphasis></superscript>The <emphasis>S. equinus</emphasis> group consists of <emphasis>S. equinus, S. gallolyticus</emphasis> subsp. <emphasis>gallolyticus, S. gallolyticus</emphasis> subsp. <emphasis>pasteurianus</emphasis>, and <emphasis>S. gallolyticus</emphasis> subsp. <emphasis>macedonicus</emphasis>; <emphasis>S. infantarius</emphasis> subsp. <emphasis>infantarius, S. lutetiensis</emphasis>, and <emphasis>S. alactolyticus</emphasis>. <emphasis>S. gallolyticus</emphasis> subsp<emphasis>. gallolyticus</emphasis> is positive for the acidification of mannitol; the other species from the <emphasis>S. equinus</emphasis> group are negative.</para>
      <para id="ch0038s000000p0048">Molecular methods may offer alternative approaches to conventional phenotypic identification schemes. The most common molecular identification method, 16S rRNA gene sequencing, does not yield reliable species identification for several species, including<emphasis>S. mitis, S. oralis</emphasis>, and <emphasis>S. pneumoniae</emphasis>. The 16S rRNA gene sequences are more than 99% identical (<link linkend="ch0038s000000li0001">1</link>). Sequence determination of the manganese-dependent superoxide dismutase gene <emphasis>sodA</emphasis> appears to be more reliable (<link linkend="ch0038s000000li0089">89</link>, <link linkend="ch0038s000000li0090">90</link>) for the differentiation of <emphasis>S. mitis, S. oralis</emphasis>, and <emphasis>S. pneumoniae</emphasis> and the correct identification of streptococcal species from the viridans group.</para>
      <para id="ch0038s000000p0049">Phenotypic descriptions of the species belonging to the viridans group streptococci (<link linkend="ch0038s000000a0007">Table 1</link>) are given below, and physiological traits of the groups are shown in <link linkend="ch0038s000000a0082">Table 3</link>.</para>
      <sect2 id="ch0038s0023s0001">
        <title>S. mitis Group</title>
        <anchor id="ch0038s000023a0002"/>
        <anchor id="ch0038s000000a0095"/>
        <para id="ch0038s000000p0050">This group of predominantly alpha-hemolytic streptococci includes several species of known clinical significance together with others for which few or no clinical data have been collected. Among the phenotypic characteristics of the species in this group, extracellular polysaccharide production is negative for<emphasis>S. mitis</emphasis> strains but is a variable characteristic of <emphasis>S. oralis</emphasis> isolates. This feature correlates with the smooth colony surface of many <emphasis>S. oralis</emphasis> strains and the rough and dry appearance of <emphasis>S. mitis</emphasis> colonies.</para>
      </sect2>
      <sect2 id="ch0038s0023s0002">
        <title>S. anginosus Group</title>
        <anchor id="ch0038s000023a0003"/>
        <anchor id="ch0038s000000a0096"/>
        <para id="ch0038s000000p0051">The small-colony-forming species of the<emphasis>S. anginosus</emphasis> group may be non-, alpha-, or beta-hemolytic on blood agar plates, with some variations between the species. While <emphasis>S. constellatus</emphasis> is frequently beta-hemolytic, most isolates of <emphasis>S. intermedius</emphasis> are nonhemolytic. For many strains, growth is enhanced in the presence of CO<subscript>2</subscript>, with some strains requiring anaerobic conditions. <emphasis>S. anginosus</emphasis> and <emphasis>S. constellatus</emphasis> strains may possess Lancefield group antigen A, C, F, or G. Most <emphasis>S. constellatus</emphasis> or <emphasis>S. intermedius</emphasis> strains react with antisera against the Lancefield group F antigen or are nongroupable.</para>
        <para id="ch0038s000000p0052">The species<emphasis>S. constellatus</emphasis> has been subdivided into the subspecies <emphasis>S. constellatus</emphasis> subsp. <emphasis>constellatus, S. constellatus</emphasis> subsp. <emphasis>pharyngis</emphasis>, and <emphasis>S. constellatus</emphasis> subsp. <emphasis>viborgensis. S. constellatus</emphasis> subsp. <emphasis>constellatus</emphasis> is phenotypically different from <emphasis>S. constellatus</emphasis> subsp. <emphasis>pharyngis</emphasis>, which usually possesses the Lancefield group antigen C, is beta-hemolytic, and has been associated with pharyngitis. Detailed phenotypic characteristics of the <emphasis>S. anginosus</emphasis> group are shown in <anchor id="ch0038s000000a0097"/><link linkend="ch0038s000000a0101">Table 4</link> (<link linkend="ch0038s000000li0002">2</link>, <link linkend="ch0038s000000li0091">91</link>, <link linkend="ch0038s000000li0092">92</link>).</para>
      </sect2>
      <sect2 id="ch0038s0023s0003">
        <title>S. mutans Group</title>
        <anchor id="ch0038s000023a0004"/>
        <anchor id="ch0038s000000a0098"/>
        <para id="ch0038s000000p0053">The species<emphasis>S. mutans</emphasis> and <emphasis>S. sobrinus</emphasis> are frequently found in human hosts, while other species of this group (<link linkend="ch0038s000000a0007">Table 1</link>) are only rarely encountered in humans or represent animal pathogens. The <emphasis>S. mutans</emphasis> group is characterized by the production of extracellular polysaccharides from sucrose, which can be tested by culturing the bacteria on sucrose-containing agar and by the ability to produce acid from a relatively wide range of carbohydrates. <emphasis>S. mutans</emphasis> strains may present with an atypical morphology for streptococci, forming short rods on solid media or in broth culture under acidic conditions. On blood agar, colonies are often hard and adherent and are usually alpha-hemolytic. Under anaerobic growth conditions, some strains are beta-hemolytic. <emphasis>S. sobrinus</emphasis> strains are mostly nonhemolytic or occasionally alpha-hemolytic. On sucrose-containing agar, species from this group form colonies that are rough (frosted glass appearance), heaped, and surrounded by liquid-containing glucan.</para>
      </sect2>
      <sect2 id="ch0038s0023s0004">
        <title>S. salivarius Group</title>
        <anchor id="ch0038s000023a0005"/>
        <anchor id="ch0038s000000a0099"/>
        <para id="ch0038s000000p0054"><emphasis>S. salivarius</emphasis> strains are usually non- or alpha-hemolytic on blood agar. On sucrose-containing agar, strains form large mucoid or hard colonies due to the production of extracellular polysaccharides. A high proportion of <emphasis>S. salivarius</emphasis> strains react with the Lancefield group K antiserum. Species in this group may also react with the streptococcal group D antiserum. It is unclear if these strains truly possess the group D antigen or yield a nonspecific cross-reaction. <emphasis>S. vestibularis</emphasis> is alpha-hemolytic, and the failure of this species to produce extracellular polysaccharides on sucrose-containing agar is helpful in distinguishing it from <emphasis>S. salivarius</emphasis> strains. <emphasis>S. salivarius</emphasis> subsp. <emphasis>thermophilus</emphasis> is found in dairy products but has not been isolated from clinical specimens.</para>
        <anchor id="ch0038s000000a0100"/>
        <beginpage pagenum="440"/>
        <table id="ch0038s000000t0004"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0038s000000a0101"/><link linkend="ch0038s000000a0097">TABLE 4</link></phrase></emphasis> Phenotypic characteristics of streptococcal species from the <emphasis>S. anginosus</emphasis> group<superscript><emphasis><anchor id="ch0038s000000a0102"/><link linkend="ch0038s000000a0105">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="4">
            <tbody>
              <row>
                <entry>Test</entry>
                <entry><phrase role="center">
                    <emphasis>S. anginosus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">
                    <emphasis>S. constellatus</emphasis>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0038s000000a0103"/>
                        <link linkend="ch0038s000000a0106">b</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
                <entry><phrase role="center">
                    <emphasis>S. intermedius</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry>β-<phrase role="small">D</phrase>-Fucosidase</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>β-<emphasis>N</emphasis>-Acetylglucosaminidase</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>β-<emphasis>N</emphasis>-Acetylgalactosaminidase</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>Neuraminidase</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>α-<phrase role="small">D</phrase>-Glucosidase</entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>β-<phrase role="small">D</phrase>-Glucosidase</entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
              </row>
              <row>
                <entry>β-<phrase role="small">D</phrase>-Galactosidase</entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>Amygdalin (acidification)</entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
              </row>
              <row>
                <entry>Mannitol (acidification)</entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry>Sorbitol (acidification)</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry>Lactose (acidification)</entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>Arginine hydrolysis</entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>Esculin hydrolysis</entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">V</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>VP<superscript><emphasis><anchor id="ch0038s000000a0104"/><link linkend="ch0038s000000a0107">c</link></emphasis></superscript></entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry>Urease</entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0105"/><link linkend="ch0038s000000a0102">a</link></emphasis></superscript>+, positive; −, negative; V, variable according to Summanen et al. (<link linkend="ch0038s000000li0091">91</link>), Facklam (<link linkend="ch0038s000000li0002">2</link>), and Whiley et al. (<link linkend="ch0038s000000li0092">92</link>).</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0106"/><link linkend="ch0038s000000a0103">b</link></emphasis></superscript><emphasis>S. constellatus</emphasis> subsp. <emphasis>pharyngis</emphasis> is β-<phrase role="small">D</phrase>-fucosidase, β-<phrase role="small">D</phrase>-acetylglucosaminidase, β-<phrase role="small">D</phrase>-acetylgalactosaminidase, and β-<phrase role="small">D</phrase>-glucosidase positive, in contrast to <emphasis>S. constellatus</emphasis> subsp. <emphasis>constellatus</emphasis>.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0038s000000a0107"/><link linkend="ch0038s000000a0104">c</link></emphasis></superscript>Voges-Proskauer test (formation of acetoin from glucose fermentation).</para>
      </sect2>
      <sect2 id="ch0038s0023s0005">
        <title>S. equinus Group</title>
        <anchor id="ch0038s000023a0006"/>
        <anchor id="ch0038s000000a0108"/>
        <para id="ch0038s000000p0055">The species belonging to this group are nonenterococcal group D streptococci that are PYR negative. Most strains grow on bile esculin agar and are unable to grow in 6.5% NaCl. On blood agar, strains are either nonhemolytic or alpha-hemolytic. Strains of the<emphasis>S. equinus</emphasis> group share phenotypic characteristics with <emphasis>S. mutans</emphasis> strains, such as production of glucan, fermentation of mannitol, and growth on bile esculin agar. However, the <emphasis>S. equinus</emphasis> group does not ferment sorbitol. <emphasis>S. gallolyticus</emphasis> subsp. <emphasis>gallolyticus</emphasis> and <emphasis>S. lutetiensis</emphasis> typically ferment starch or glycogen and give a Lancefield group D reaction, in contrast to <emphasis>S. gallolyticus</emphasis> subsp. <emphasis>pasteurianus</emphasis>. A detailed phenotypic characterization and emended description of the different subspecies can be found in reference <link linkend="ch0038s000000li0044">44</link>. For the identification of species in this group, tests for β-glucuronidase, α- and β-galactosidase, β-mannosidase, and acid production from starch, glycogen, inulin, and mannitol are helpful. Strains formerly known as <emphasis>S. bovis</emphasis> currently belong to several species of the <emphasis>S. equinus</emphasis> group.</para>
      </sect2>
      <sect2 id="ch0038s0023s0006">
        <title>Phenotypic Tests for Identification of S. pneumoniae and Viridans Group Streptococci</title>
        <anchor id="ch0038s000023a0007"/>
        <anchor id="ch0038s000000a0109"/>
        <sect3 id="ch0038s0023s0006s0001">
          <title>Optochin Test</title>
          <anchor id="ch0038s000023a0008"/>
          <anchor id="ch0038s000000a0110"/>
          <para id="ch0038s000000p0056">Most<emphasis>S. pneumoniae</emphasis> isolates are optochin susceptible. Before application of the optochin disk, several colonies of a pure culture are streaked on a sheep blood agar plate. Optochin testing should be performed on plates that are incubated at 35 to 36°C overnight in 5% CO<subscript>2</subscript> because up to 8% of strains do not grow under ambient conditions. <emphasis>S. pneumoniae</emphasis> isolates show zones of inhibition of ≥14 mm with a 6-mm disk (containing 5 μg of optochin) and zones of inhibition of ≥16 mm with a 10-mm disk. Incubation in 5% CO<subscript>2</subscript> yields increased specificity (<link linkend="ch0038s000000li0036">36</link>, <link linkend="ch0038s000000li0079">79</link>). Optochin-resistant <emphasis>S. pneumoniae</emphasis> strains have been reported, as have optochin-susceptible <emphasis>S. mitis</emphasis> isolates (especially when tested under ambient conditions). Since optochin testing may miss between 4 and 11% of bile-soluble <emphasis>S. pneumoniae</emphasis> isolates (<link linkend="ch0038s000000li0036">36</link>, <link linkend="ch0038s000000li0079">79</link>), strains displaying a smaller zone of inhibition (9 to 13 mm for the 6-mm disk) should be subjected to additional testing (e.g., bile solubility and genetic testing) to confirm species identification.</para>
          <para id="ch0038s000000p0057">Application of an optochin disk onto the primary culture medium may facilitate a rapid presumptive identification but may miss pneumococcal isolates in a mixed culture. The optochin susceptibility test should be repeated with a pure culture in cases of mixed cultures, or additional tests should be performed (e.g., bile solubility).</para>
        </sect3>
        <sect3 id="ch0038s0023s0006s0002">
          <title>Bile Solubility Test</title>
          <anchor id="ch0038s000023a0009"/>
          <anchor id="ch0038s000000a0111"/>
          <para id="ch0038s000000p0058">The bile solubility test can be performed either in a test tube or by direct application of the reagent to an agar plate. For the test tube method, a saline suspension of a pure culture is adjusted to a McFarland standard of 0.5 to 1.0, and 0.5 ml of the suspension is added to a small tube. The bacterial suspension is mixed with 0.5 ml of 10% sodium deoxycholate (bile) and incubated at 35°C. A control containing 0.5 ml of bacterial suspension with 0.5 ml of saline should be prepared for each strain tested. A positive result is characterized by clearing of the bile suspension within 3 h; clearing can start as early as 5 to 15 min after inoculation and allows the identification of a strain as<emphasis>S. pneumoniae</emphasis>. A rapid densitometer-based test tube method that is evaluated after 10 min of incubation time has been published (<link linkend="ch0038s000000li0093">93</link>). For the plate method, 1 drop of 10% sodium deoxycholate is placed directly on a colony of the strain in question and incubated at 35°C for 15 to 30 min in ambient air. It is important to keep the plates in a horizontal position to prevent the reagent from washing away the colony. Colonies of <emphasis>S. pneumoniae</emphasis> disappear or demonstrate a flattened colony morphology, while other viridans group streptococci appear unchanged. In contrast to optochin susceptibility, bile solubility testing demonstrates good sensitivity and specificity (<link linkend="ch0038s000000li0079">79</link>).</para>
          <anchor id="ch0038s000000a0112"/>
          <beginpage pagenum="441"/>
        </sect3>
        <sect3 id="ch0038s0023s0006s0003">
          <title>Bile Esculin Test</title>
          <anchor id="ch0038s000023a0010"/>
          <anchor id="ch0038s000000a0113"/>
          <para id="ch0038s000000p0059">Bile esculin medium (available from commercial sources) in either plates or slants should be inoculated with one to three colonies of the organism to be tested and incubated at 35°C in ambient air for up to 48 h. Optimal results can be achieved by using medium supplemented with 4% oxgall (equivalent of 40% bile) (Remel, Lenexa, KS) and a standardized inoculum of 10<superscript>6</superscript> CFU (<link linkend="ch0038s000000li0094">94</link>). A definitive blackening of plated medium or blackening of at least half of an agar slant is considered a positive test, indicative of species belonging to the <emphasis>S. equinus</emphasis> group or enterococci. Occasional other viridans group streptococci are positive with this test or display weakly positive reactions that are difficult to interpret. Isolates from patients with serious infections (e.g., endocarditis) should be more completely characterized.</para>
        </sect3>
        <sect3 id="ch0038s0023s0006s0004">
          <title>Arginine Hydrolysis</title>
          <anchor id="ch0038s000023a0011"/>
          <anchor id="ch0038s000000a0114"/>
          <para id="ch0038s000000p0060">Arginine hydrolysis is a key reaction for the identification of viridans group streptococci. To detect arginine dihydrolase activity, Moeller’s decarboxylase broth containing arginine (Becton Dickinson, Franklin Lakes, NJ, and other sources) is inoculated as described elsewhere in this<emphasis>Manual</emphasis> and incubated at 35 to 37°C for up to 7 days.</para>
        </sect3>
        <sect3 id="ch0038s0023s0006s0005">
          <title>Urea Hydrolysis, Esculin Hydrolysis, and VP Test</title>
          <anchor id="ch0038s000023a0012"/>
          <anchor id="ch0038s000000a0115"/>
          <para id="ch0038s000000p0061">Christensen urea agar (Becton Dickinson and other sources) is inoculated and incubated aerobically at 35°C for up to 7 days. Development of a pink color indicates a positive reaction. An alternative format is to dispense Christensen medium without agar into a microtiter tray well and, after inoculation, overlay it with mineral oil prior to incubation. For the detection of esculin hydrolysis, esculin agar slants (Becton Dickinson and other sources) are inoculated and incubated for up to 1 week. A positive reaction appears as a blackening of the medium; no change in color indicates a negative esculin hydrolysis test. The VP test is described above for the identification of beta-hemolytic streptococci. A standard method for performing the VP test, requiring extended incubation, can be found elsewhere in this<emphasis>Manual</emphasis>.</para>
        </sect3>
        <sect3 id="ch0038s0023s0006s0006">
          <title>Hyaluronidase Production</title>
          <anchor id="ch0038s000023a0013"/>
          <anchor id="ch0038s000000a0116"/>
          <para id="ch0038s000000p0062">Hyaluronidase activity can be detected on brain heart infusion agar plates supplemented with 2 mg/liter of sodium hyaluronate (Sigma-Aldrich, St. Louis, MO). The strains to be tested are inoculated by stabbing into the agar, and plates are incubated anaerobically at 37°C overnight. After the plate is flooded with 2 M acetic acid, hyaluronidase activity is indicated by the appearance of a clear zone around the stab. A quantitative method for determining hyaluronidase activity can be performed in microtiter trays (<link linkend="ch0038s000000li0095">95</link>).</para>
        </sect3>
        <sect3 id="ch0038s0023s0006s0007">
          <title>Production of Extracellular Polysaccharide</title>
          <anchor id="ch0038s000023a0014"/>
          <anchor id="ch0038s000000a0117"/>
          <para id="ch0038s000000p0063">Strains may be isolated as single colonies on sucrose-containing agar. The two most commonly used media are (i) mitis-salivarius agar containing 0.001% (wt/vol) potassium tellurite (Becton Dickinson) and (ii) tryptone-yeast-cystine agar (Lab M, Bury, United Kingdom). Incubation may require up to 5 days at 37°C under anaerobic incubation conditions.</para>
        </sect3>
      </sect2>
      <sect2 id="ch0038s0023s0007">
        <title>TYPING SYSTEMS</title>
        <anchor id="ch0038s000023a0015"/>
        <anchor id="ch0038s000000a0118"/>
        <para id="ch0038s000000p0064">In the majority of cases, typing of streptococci has no immediate clinical or therapeutic consequences. It is most often performed by reference laboratories for the purposes of epidemiologic studies and the evaluation of vaccine efficacy. Although classical antibody-dependent typing systems for capsular serotypes and surface proteins have been used for many years, molecular methods are increasingly being applied. Molecular methods do not require the maintenance of rarely used reagents, such as a large antibody panel, and are independent of culture conditions and gene expression. For the differentiation of distinct clones, pulsed-field gel electrophoresis and multilocus sequence typing (MLST) systems have been established for many streptococcal species (<link linkend="ch0038s000000li0096">96</link>). More recently, genomic bioinformatic analysis tools have been successfully developed for <emphasis>Streptococcus</emphasis> spp. to determine serotypes (<link linkend="ch0038s000000li0097">97</link>–<link linkend="ch0038s000000li0101">101</link>), MLST patterns (<link linkend="ch0038s000000li0102">102</link>), toxin typing, and identification of virulence factors (<link linkend="ch0038s000000li0103">103</link>, <link linkend="ch0038s000000li0104">104</link>), enabling comprehensive assessments of isolates. Sequencing an entire bacterial genome reveals variations in sequences such as single-nucleotide polymorphisms and other nucleotide level differences and offers maximum discriminatory power necessary to support outbreak investigations, determine transmission events, monitor trends, and identify the emergence of novel mutations (<link linkend="ch0038s000000li0105">105</link>, <link linkend="ch0038s000000li0106">106</link>).</para>
        <para id="ch0038s000000p0065"><emphasis>S. pneumoniae</emphasis> currently comprises 100 capsular serotypes. Pneumococcal capsule typing can be done by both molecular based assays and the classic Neufeld test (Quellung reaction). For the Quellung reaction, pure cultures of pneumococci are grown on a freshly prepared 5% sheep blood agar plate or a 10% horse blood agar plate at 35 to 37°C and 5% CO<subscript>2</subscript> for 18 to 24 h. A small amount of bacterial growth (less than a 10-μl loop) is resuspended in a droplet of phosphate-buffered or physiological saline (approximately McFarland 0.5). A few microliters of the saline suspension is mixed with an equal amount of specific pneumococcal rabbit antisera on a glass slide. The specimen is subsequently evaluated for capsular swelling (a clear area surrounding the bacterial cells) by phase-contrast microscopy (×1,000 magnification; oil immersion) (<link linkend="ch0038s000000li0107">107</link>). Following the same principle, commercially available kits (Pneumotest; Statens Serum Institut, Copenhagen, Denmark) allow rapid testing of <emphasis>S. pneumoniae</emphasis> serotypes with pooled antisera by a checkerboard method. A rapid antigen detection test using pooled antisera coupled to latex beads (Statens Serum Institut) has been developed (<link linkend="ch0038s000000li0108">108</link>). Due to strain discrepancies, confirmation by the Neufeld Quellung reaction is recommended. PCR methods for pneumococcal serotype determination are available (<link linkend="ch0038s000000li0109">109</link>, <link linkend="ch0038s000000li0110">110</link>). WGS has also been used to predict <emphasis>S. pneumoniae</emphasis> serotypes (<link linkend="ch0038s000000li0097">97</link>–<link linkend="ch0038s000000li0099">99</link>). For the distinction of single clones, pulsed-field gel electrophoresis, MLST typing schemes, and WGS can be used in pneumococcal investigations.</para>
        <para id="ch0038s000000p0066">Ten antibody-defined capsular polysaccharides have been described for<emphasis>S. agalactiae</emphasis> (Ia, Ib, and II to IX). The percentage of nontypeable strains can be minimized by optimization of capsular expression, which can be accomplished by harvesting cells grown to log phase in Todd-Hewitt broth with added glucose and sodium phosphate (<link linkend="ch0038s000000li0111">111</link>). In addition to antibody detection of capsular serotypes, PCR- and sequencing-based techniques allow the detection of capsular serotypes (<link linkend="ch0038s000000li0100">100</link>, <link linkend="ch0038s000000li0112">112</link>, <link linkend="ch0038s000000li0113">113</link>). Individual clones of <emphasis>S. agalactiae</emphasis> have been detected either by MLST or pulsed-field gel electrophoresis.</para>
        <para id="ch0038s000000p0067">Traditional typing of<emphasis>S. pyogenes</emphasis> is based upon the antigenic specificity of the surface-expressed T and M proteins. The trypsin-resistant T protein is part of the pilus structures (<link linkend="ch0038s000000li0114">114</link>). The T type can be identified by agglutination with commercially available serologic assays utilizing approximately 20 accepted anti-T sera. M proteins are major antiphagocytic virulence factors of <emphasis>S. pyogenes</emphasis> (<link linkend="ch0038s000000li0115">115</link>). N-terminal sequence variation of these highly protective antigens is the basis of the <emphasis>S. pyogenes</emphasis> precipitation typing system. At least 100 M serotypes have been described.</para>
        <anchor id="ch0038s000000a0119"/>
        <beginpage pagenum="442"/>
        <para id="ch0038s000000p0068">Molecular typing of<emphasis>S. pyogenes</emphasis> relies on the nucleotide sequences encoding the amino termini of M proteins, the <emphasis>emm</emphasis> genes. These correlate with Lancefield M serotypes and allow assignment to a validated M protein gene sequence. The identification of new <emphasis>emm</emphasis> sequence types is easy and represents the current standard of <emphasis>S. pyogenes</emphasis> typing (<link linkend="ch0038s000000li0116">116</link>). The CDC maintains a large database of approximately 380 <emphasis>emm</emphasis> gene sequences from strains originally used for Lancefield serotyping, including <emphasis>emm</emphasis> sequences from beta-hemolytic group C, G, and L streptococci (<ulink url="https://www.cdc.gov/streplab/groupa-strep/emm-background.html">https://www.cdc.gov/streplab/groupa-strep/emm-background.html</ulink>). Recently, a modified <emphasis>emm</emphasis> typing system for <emphasis>S. pyogenes</emphasis> based on clusters of M proteins that correlate to function has been adopted (<link linkend="ch0038s000000li0117">117</link>). Bioinformatic tools for <emphasis>emm</emphasis> typing have been developed (<link linkend="ch0038s000000li0118">118</link>).</para>
        <para id="ch0038s000000p0069">An MLST scheme is also available for<emphasis>S. pyogenes</emphasis>. Population genetic studies demonstrated stable associations between <emphasis>emm</emphasis> type and MLST among isolates obtained decades apart and/or on different continents (<link linkend="ch0038s000000li0119">119</link>).</para>
      </sect2>
      <sect2 id="ch0038s0023s0008">
        <title>SEROLOGIC TESTS</title>
        <anchor id="ch0038s000023a0016"/>
        <anchor id="ch0038s000000a0120"/>
        <para id="ch0038s000000p0070">Determination of streptococcal antibodies is indicated for the diagnosis of poststreptococcal disease, such as acute rheumatic fever or glomerulonephritis (<link linkend="ch0038s000000li0120">120</link>). A 4-fold rise in antibody titer is regarded as definitive proof of an antecedent streptococcal infection. Multiple variables, including site of infection, time since the onset of infection, age, background prevalence of streptococcal infections, antimicrobial therapy, and other comorbidities, influence antibody levels (<link linkend="ch0038s000000li0121">121</link>). The most widely used antibodies are anti-streptolysin O and anti-DNase B.</para>
        <para id="ch0038s000000p0071">Antibodies against streptolysin O (ASO) reach a maximum at 3 to 6 weeks after infection. While ASO responses following streptococcal upper respiratory tract infections are usually elevated, pyoderma caused by<emphasis>S. pyogenes</emphasis> does not elicit a strong ASO response. <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> can also produce streptolysin O, and thus, elevated ASO titers are not specific to <emphasis>S. pyogenes</emphasis> infections.</para>
        <para id="ch0038s000000p0072">Among the four streptococcal DNases produced, the host response is most consistent against DNase B. Anti-DNase B titers may not reach maxima for 6 to 8 weeks but remain elevated longer than ASO titers and are more reliable than ASO for the confirmation of a preceding streptococcal skin infection. Moreover, since only 80 to 85% of patients with rheumatic fever have elevated ASO titers, additional anti-DNase B titers may be helpful.</para>
        <para id="ch0038s000000p0073">Due to frequent exposure to<emphasis>S. pyogenes</emphasis>, ASO and anti-DNase B titers are higher in children from 2 to 12 years of age than adults in the United States. Geometric mean values are 89 Todd units for ASO and 112 units for anti-DNase B, while the upper limits of normal values are 240 Todd units (ASO) and 640 units (anti-DNase B) (<link linkend="ch0038s000000li0122">122</link>). Prompt antibiotic therapy for streptococcal infections can reduce the titer but does not abolish antibody production. Streptococcal carriers do not experience a rise in streptococcal antibody titers.</para>
      </sect2>
      <sect2 id="ch0038s0023s0009">
        <title>ANTIMICROBIAL SUSCEPTIBILITIES</title>
        <anchor id="ch0038s000023a0017"/>
        <anchor id="ch0038s000000a0121"/>
      </sect2>
    </sect1>
    <sect1 id="ch0038s0024">
      <title>Beta-Hemolytic Streptococci</title>
      <anchor id="ch0038s000024a0001"/>
      <anchor id="ch0038s000000a0122"/>
      <para id="ch0038s000000p0074">Penicillin remains the drug of choice for the empirical treatment of streptococcal infections due to<emphasis>S. pyogenes</emphasis>, because in contrast to <emphasis>S. pneumoniae</emphasis> and other alpha-hemolytic streptococci, <emphasis>S. pyogenes</emphasis> remains uniformly susceptible to penicillin. Reports about reduced penicillin susceptibility in strains of <emphasis>S. pyogenes</emphasis> have not been confirmed by reference laboratories. This is, however, no longer true for <emphasis>S. agalactiae</emphasis>. The emergence of diminished susceptibility to penicillin G caused by a mutation of the penicillin-binding proteins, Pbp2x, in isolated strains in Asia and the United States has been reported (<link linkend="ch0038s000000li0123">123</link>, <link linkend="ch0038s000000li0124">124</link>). Due to suspected or confirmed penicillin allergies, macrolides and clindamycin are often given as an alternative treatment. Macrolide resistance rates among isolates of <emphasis>S. pyogenes</emphasis> and <emphasis>S. agalactiae</emphasis> have been increasing in North America, Asia, and Europe (<link linkend="ch0038s000000li0125">125</link>). Resistance rates correlate with the use of macrolides in clinical practice, and geographic differences in resistance rates are often due to differences in macrolide use. In the United States, invasive <emphasis>S. agalactiae</emphasis> isolates from nonpregnant adults demonstrated resistance rates of 55% and 43% to erythromycin and clindamycin, respectively, between 2011 and 2016 (<link linkend="ch0038s000000li0126">126</link>). While isolates with a reduced susceptibility to glycopeptides have not been found in <emphasis>S. pyogenes</emphasis>, very rare <emphasis>S. agalactiae</emphasis> isolates from invasive infections can harbor <emphasis>vanG</emphasis> resistance genes (<link linkend="ch0038s000000li0127">127</link>, <link linkend="ch0038s000000li0128">128</link>). Due to the uniform susceptibility of <emphasis>S. pyogenes</emphasis> to penicillin, susceptibility testing for penicillins or other β-lactams approved for treatment of <emphasis>S. pyogenes</emphasis> and <emphasis>S. agalactiae</emphasis> is not necessary for clinical purposes. So far, the rare isolates of <emphasis>S. agalactiae</emphasis> with reduced susceptibility to penicillin have not resulted in a change of this recommendation. Susceptibility testing for macrolides should be performed using erythromycin, since resistance and susceptibility of azithromycin, clarithromycin, and dirithromycin can be predicted by testing erythromycin. As specified in the ASM guidelines (<link linkend="ch0038s000000li0025">25</link>), <emphasis>S. agalactiae</emphasis> isolates from pregnant women with severe penicillin allergy should be tested for erythromycin and clindamycin resistance, including constitutive and inducible clindamycin resistance testing. Clindamycin only (not erythromycin) and vancomycin susceptibility results should be reported for intrapartum prophylaxis for severely penicillin-allergic patients.</para>
      <para id="ch0038s000000p0075">Fluoroquinolone resistance among streptococci is a growing concern, and fluoroquinolones should not be used as first-line treatment for invasive infections caused by pyogenic streptococci. Point mutations in the<emphasis>gyrA</emphasis> and <emphasis>parC</emphasis> genes contribute to fluoroquinolone resistance (<link linkend="ch0038s000000li0129">129</link>). A high prevalence of fluoroquinolone-resistant <emphasis>S. agalactiae</emphasis> has been reported in Asia (<link linkend="ch0038s000000li0130">130</link>). Beta-hemolytic streptococci are susceptible to linezolid and daptomycin (<link linkend="ch0038s000000li0131">131</link>), but their clinical efficacy and potential for resistance development have not been investigated.</para>
      <para id="ch0038s000000p0076">WGS tools exist to predict the antimicrobial susceptibilities of<emphasis>S. agalactiae</emphasis> isolates (<link linkend="ch0038s000000li0100">100</link>).</para>
    </sect1>
    <sect1 id="ch0038s0025">
      <title>S. pneumoniae and Viridans Group Streptococci</title>
      <anchor id="ch0038s000025a0001"/>
      <anchor id="ch0038s000000a0123"/>
      <para id="ch0038s000000p0077">In view of the development of penicillin resistance in<emphasis>S. pneumoniae</emphasis> and other alpha-hemolytic streptococci, penicillin can no longer be recommended as the empiric treatment of choice in many countries. Penicillin is considered a preferred antimicrobial agent only for <emphasis>S. pneumoniae</emphasis> and other alpha-hemolytic streptococci with demonstrated susceptibilities to this antibiotic. Penicillin resistance in <emphasis>S. pneumoniae</emphasis> is caused by altered penicillin-binding proteins. In 2018, &lt;5% of strains were reported as nonsusceptible to penicillin in the Active Bacterial Core surveillance (ABCs) data (<ulink url="http://www.cdc.gov/abcs/reports-findings/survreports/spneu18.pdf">http://www.cdc.gov/abcs/reports-findings/survreports/spneu18.pdf</ulink>). Susceptibility to penicillin can be determined by a disk diffusion test with 1 μg of oxacillin. According to the current CLSI guidelines, in all cases where oxacillin zones sizes (≤19 mm) indicate a reduced penicillin susceptibility, MIC determinations for penicillin should be performed (<link linkend="ch0038s000000li0132">132</link>). For susceptibility testing of all other β-lactams in <emphasis>S. pneumoniae</emphasis>, MIC determinations are recommended. Macrolide resistance rates of 29% for <emphasis>S. pneumoniae</emphasis> were reported by the ABCs study. Fluoroquinolone resistance in <emphasis>S. pneumoniae</emphasis> occurs in a stepwise fashion and is due to mutations in DNA topoisomerase IV (<emphasis>parC</emphasis>) and/or a subunit of DNA gyrase (<emphasis>gyrA</emphasis>). While the overall prevalence of fluoroquinolone resistance remains below 1% according to the 2018 ABCs study, clinical failures of levofloxacin therapy due to resistance have been reported (<link linkend="ch0038s000000li0133">133</link>). Vancomycin-resistant <emphasis>S. pneumoniae</emphasis> isolates have not been described. <emphasis>S. pneumoniae</emphasis> infections should be treated according to current guidelines (<link linkend="ch0038s000000li0134">134</link>). Depending on the clinical situation, treatment options include penicillin, extended-spectrum cephalosporins, macrolides, fluoroquinolones, and vancomycin.</para>
      <anchor id="ch0038s000000a0124"/>
      <beginpage pagenum="443"/>
      <para id="ch0038s000000p0078">WGS tools exist to predict the antimicrobial susceptibilities of<emphasis>S. pneumoniae</emphasis> isolates (<link linkend="ch0038s000000li0101">101</link>).</para>
      <para id="ch0038s000000p0079">In a recent study of viridans group streptococci isolated from hospitalized patients in the United States and Europe, 74.8% were susceptible to penicillin (<link linkend="ch0038s000000li0135">135</link>). Because of allergies and other reasons, newer antimicrobial agents are often used for <emphasis>S. mitis</emphasis> and other viridans group streptococci. However, <emphasis>S. mitis</emphasis> isolates may rapidly develop resistance when treated with daptomycin (<link linkend="ch0038s000000li0136">136</link>). Although most isolates are susceptible to vancomycin (<link linkend="ch0038s000000li0135">135</link>), isolation of vancomycin-resistant viridans group streptococci from the <emphasis>S. equinus</emphasis> and <emphasis>S. anginosus</emphasis> groups has been reported (<link linkend="ch0038s000000li0128">128</link>, <link linkend="ch0038s000000li0137">137</link>).</para>
      <sect2 id="ch0038s0025s0001">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0038s000025a0002"/>
        <anchor id="ch0038s000000a0125"/>
        <para id="ch0038s000000p0080">Streptococci from the pyogenic group are important human pathogens. Timely identification of these species in clinical specimens is therefore crucial to treat infections adequately and to reduce transmission. Pharyngitis caused by<emphasis>S. pyogenes</emphasis> remains a substantial health problem in childhood and adolescence. Diagnosis by rapid antigen tests, NAAT, or bacteriological culture minimizes unjustified antibiotic treatment of viral pharyngitis. Serologic tests are usually applied in cases of suspected poststreptococcal sequelae. Proper identification and reporting should not be limited to <emphasis>S. pyogenes</emphasis>, since <emphasis>S. dysgalactiae</emphasis> subsp. <emphasis>equisimilis</emphasis> (human group C and G streptococci) has been documented as an agent of pharyngitis, including cases complicated by nonsuppurative sequelae. In this context, it is important to correctly differentiate these pathogens from the small-colony-forming beta-hemolytic species of the <emphasis>S. anginosus</emphasis> group that compose part of the oropharyngeal microbiota. While invasive neonatal <emphasis>S. agalactiae</emphasis> infections are declining due to improved prenatal screening and peripartum antibiotic prophylaxis, increased detection of <emphasis>S. agalactiae</emphasis> from adult patients has been reported (<link linkend="ch0038s000000li0026">26</link>). Thorough identification and reporting of this organism should therefore not be confined to screening swabs during pregnancy or in newborns. In the same context, it is important to test for inducible clindamycin resistance prior to reporting clindamycin susceptibility for beta-hemolytic streptococci.</para>
        <para id="ch0038s000000p0081">Despite the fact that<emphasis>S. pneumoniae</emphasis> is often found as a colonizer in respiratory samples, it should always be distinguished from viridans group streptococci and reported. Culture methods remain the mainstay in pneumococcal pneumonia and sepsis as well as meningitis. To enable the initiation of adequate antibiotic treatment, resistance testing should be performed for all isolates. Special care should be taken to ensure the reporting of the correct β-lactam breakpoints for non-CSF and CSF isolates. If antibiotic treatment was started before microbiological samples were obtained, the urinary or CSF antigen test or nucleic acid detection techniques may help to properly identify the causative agent, especially in invasive infections.</para>
        <para id="ch0038s000000p0082">The correct identification of viridans group streptococci and the distinction of strains causing infections from isolates of the physiological microbiota remain a major challenge. Identification to the group or species level should be confined to strains causing abscesses, endocarditis, and serious infections in neutropenic patients. For isolates causing infective endocarditis, the penicillin MIC influences the treatment plan. Many<emphasis>S. mitis</emphasis> isolates are no longer penicillin susceptible. Due to the association of <emphasis>S. gallolyticus</emphasis> subsp. <emphasis>gallolyticus</emphasis> with malignancies of the gastrointestinal tract, and in view of the taxonomic changes within the <emphasis>S. equinus</emphasis> group, reports of novel species designations should include the information that the species belongs to the <emphasis>S. equinus</emphasis> group (<link linkend="ch0038s000000li0138">138</link>).</para>
      </sect2>
      <sect2 id="ch0038s0025s0002">
        <title>REFERENCES</title>
        <anchor id="ch0038s000025a0003"/>
        <anchor id="ch0038s000000a0126"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0038s000000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Kawamura Y, Hou XG, Sultana F, Miura H, Ezaki T.</emphasis> 1995. Determination of 16S rRNA sequences of <emphasis><citetitle>Streptococcus mitis</citetitle></emphasis> and <emphasis><citetitle>Streptococcus gordonii</citetitle></emphasis> and phylogenetic relationships among members of the genus <emphasis><citetitle>Streptococcus</citetitle></emphasis>. <emphasis><citetitle>Int J Syst Bacteriol</citetitle></emphasis> <emphasis role="strong">45:</emphasis>406–408.</para>
          </listitem>
          <listitem id="ch0038s000000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Facklam R.</emphasis> 2002. What happened to the streptococci: overview of taxonomic and nomenclature changes. <emphasis><citetitle>Clin Microbiol Rev</citetitle></emphasis> <emphasis role="strong">15:</emphasis>613–630.</para>
          </listitem>
          <listitem id="ch0038s000000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Jensen A, Scholz CFP, Kilian M.</emphasis> 2016. Re-evaluation of the taxonomy of the Mitis group of the genus <emphasis><citetitle>Streptococcus</citetitle></emphasis> based on whole genome phylogenetic analyses, and proposed reclassification of <emphasis><citetitle>Streptococcus dentisani</citetitle></emphasis> as <emphasis><citetitle>Streptococcus oralis</citetitle></emphasis> subsp. <emphasis><citetitle>dentisani</citetitle></emphasis> comb. nov., <emphasis><citetitle>Streptococcus tigurinus</citetitle></emphasis> as <emphasis><citetitle>Streptococcus oralis</citetitle></emphasis> subsp. <emphasis><citetitle>tigurinus</citetitle></emphasis> comb. nov., and <emphasis><citetitle>Streptococcus oligofermentans</citetitle></emphasis> as a later synonym of <emphasis><citetitle>Streptococcus cristatus</citetitle></emphasis>. <emphasis><citetitle>Int J Syst Evol Microbiol</citetitle></emphasis> <emphasis role="strong">66:</emphasis>4803–4820.</para>
          </listitem>
          <listitem id="ch0038s000000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Jensen A, Hoshino T, Kilian M.</emphasis> 2013. Taxonomy of the Anginosus group of the genus <emphasis><citetitle>Streptococcus</citetitle></emphasis> and description of <emphasis><citetitle>Streptococcus anginosus</citetitle></emphasis> subsp. <emphasis><citetitle>whileyi</citetitle></emphasis> subsp. nov. and <emphasis><citetitle>Streptococcus constellatus</citetitle></emphasis> subsp. <emphasis><citetitle>viborgensis</citetitle></emphasis> subsp. nov. <emphasis><citetitle>Int J Syst Evol Microbiol</citetitle></emphasis> <emphasis role="strong">63:</emphasis>2506–2519.</para>
          </listitem>
          <listitem id="ch0038s000000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Schlegel L, Grimont F, Ageron E, Grimont PAD, Bouvet A.</emphasis> 2003. Reappraisal of the taxonomy of the <emphasis><citetitle>Streptococcus bovis</citetitle></emphasis>/<emphasis><citetitle>Streptococcus equinus</citetitle></emphasis> complex and related species: description of <emphasis><citetitle>Streptococcus gallolyticus</citetitle></emphasis> subsp. <emphasis><citetitle>gallolyticus</citetitle></emphasis> subsp. nov., <emphasis><citetitle>S. gallolyticus</citetitle></emphasis> subsp. <emphasis><citetitle>macedonicus</citetitle></emphasis> subsp. nov. and <emphasis><citetitle>S. gallolyticus</citetitle></emphasis> subsp. <emphasis><citetitle>pasteurianus</citetitle></emphasis> subsp. nov. <emphasis><citetitle>Int J Syst Evol Microbiol</citetitle></emphasis> <emphasis role="strong">53:</emphasis>631–645.</para>
          </listitem>
          <listitem id="ch0038s000000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Schlegel L, Grimont F, Collins MD, Régnault B, Grimont PA, Bouvet A.</emphasis> 2000. <emphasis><citetitle>Streptococcus infantarius</citetitle></emphasis> sp. nov., <emphasis><citetitle>Streptococcus infantarius</citetitle></emphasis> subsp. <emphasis><citetitle>infantarius</citetitle></emphasis> subsp. nov. and <emphasis><citetitle>Streptococcus infantarius</citetitle></emphasis> subsp. <emphasis><citetitle>coli</citetitle></emphasis> subsp. nov., isolated from humans and food. <emphasis><citetitle>Int J Syst Evol Microbiol</citetitle></emphasis> <emphasis role="strong">50:</emphasis>1425–1434.</para>
          </listitem>
          <listitem id="ch0038s000000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Poyart C, Quesne G, Trieu-Cuot P.</emphasis> 2002. Taxonomic dissection of the <emphasis><citetitle>Streptococcus bovis</citetitle></emphasis> group by analysis of manganese-dependent superoxide dismutase gene (sodA) sequences: reclassification of ‘<emphasis><citetitle>Streptococcus infantarius</citetitle></emphasis> subsp. <emphasis><citetitle>coli</citetitle></emphasis>’ as <emphasis><citetitle>Streptococcus lutetiensis</citetitle></emphasis> sp. nov. and of <emphasis><citetitle>Streptococcus bovis</citetitle></emphasis> biotype 11.2 as <emphasis><citetitle>Streptococcus pasteurianus</citetitle></emphasis> sp. nov. <emphasis><citetitle>Int J Syst Evol Microbiol</citetitle></emphasis> <emphasis role="strong">52:</emphasis>1247–1255.</para>
          </listitem>
          <listitem id="ch0038s000000li0008" role="bibliographyEntry">
            <anchor id="ch0038s000000a0127"/>
            <para>8.<emphasis role="strong">Rurangirwa FR, Teitzel CA, Cui J, French DM, McDonough PL, Besser T.</emphasis> 2000. <emphasis><citetitle>Streptococcus didelphis</citetitle></emphasis> sp. nov., a streptococcus with marked catalase activity isolated from opossums (<emphasis><citetitle>Didelphis virginiana</citetitle></emphasis>) with suppurative dermatitis and liver fibrosis. <emphasis><citetitle>Int J Syst Evol Microbiol</citetitle></emphasis> <emphasis role="strong">50:</emphasis>759–765.</para>
          </listitem>
          <listitem id="ch0038s000000li0009" role="bibliographyEntry">
            <para>9. GBD 2016 Lower Respiratory Infections Collaborators<emphasis role="strong">.</emphasis> 2018. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <emphasis><citetitle>Lancet Infect Dis</citetitle></emphasis> 18<emphasis role="strong">:</emphasis>1191–1210.</para>
          </listitem>
          <listitem id="ch0038s000000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Greenberg D, Broides A, Blancovich I, Peled N, Givon-Lavi N, Dagan R.</emphasis> 2004. Relative importance of nasopharyngeal versus oropharyngeal sampling for isolation of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> and <emphasis><citetitle>Haemophilus influenzae</citetitle></emphasis> from healthy and sick individuals varies with age. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">42:</emphasis>4604–4609.</para>
          </listitem>
          <listitem id="ch0038s000000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Carapetis JR, Steer AC, Mulholland EK, Weber M.</emphasis> 2005. The global burden of group A streptococcal diseases. <emphasis><citetitle>Lancet Infect Dis</citetitle></emphasis> <emphasis role="strong">5:</emphasis>685–694.</para>
          </listitem>
          <listitem id="ch0038s000000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Brouwer S, Lacey JA, You Y, Davies MR, Walker MJ.</emphasis> 2019. Scarlet fever changes its spots. <emphasis><citetitle>Lancet Infect Dis</citetitle></emphasis> <emphasis role="strong">19:</emphasis>1154–1155.</para>
          </listitem>
          <listitem id="ch0038s000000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Fulde M, Valentin-Weigand P.</emphasis> 2013. Epidemiology and pathogenicity of zoonotic streptococci. <emphasis><citetitle>Curr Top Microbiol Immunol</citetitle></emphasis> <emphasis role="strong">368:</emphasis>49–81.</para>
          </listitem>
          <listitem id="ch0038s000000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Kalimuddin S, Chen SL, Lim CTK, Koh TH, Tan TY, Kam M, Wong CW, Mehershahi KS, Chau ML, Ng LC, Tang WY, Badaruddin H, Teo J, Apisarnthanarak A, Suwantarat N, Ip M, Holden MTG, Hsu LY, Barkham T, Singapore Group B Streptococcus Consortium.</emphasis> 2017. 2015 Epidemic of severe Streptococcus agalactiae sequence type 283 infections in Singapore associated with the consumption of raw freshwater fish: a detailed analysis of clinical, epidemiological, and bacterial sequencing data. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">64</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S145–S152.</para>
          </listitem>
          <listitem id="ch0038s000000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Brandt CM, Spellerberg B.</emphasis> 2009. Human infections due to <emphasis><citetitle>Streptococcus dysgalactiae</citetitle></emphasis> subspecies <emphasis><citetitle>equisimilis</citetitle></emphasis>. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">49:</emphasis>766–772.</para>
          </listitem>
          <listitem id="ch0038s000000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Jensen A, Kilian M.</emphasis> 2012. Delineation of <emphasis><citetitle>Streptococcus dysgalactiae</citetitle></emphasis>, its subspecies, and its clinical and phylogenetic relationship to <emphasis><citetitle>Streptococcus pyogenes</citetitle></emphasis>. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">50:</emphasis>113–126.</para>
          </listitem>
          <listitem id="ch0038s000000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A, Sriprakash KS, Sanderson-Smith ML, Nizet V.</emphasis> 2014. Disease manifestations and pathogenic mechanisms of group A <emphasis><citetitle>Streptococcus</citetitle></emphasis>. <emphasis><citetitle>Clin Microbiol Rev</citetitle></emphasis> <emphasis role="strong">27:</emphasis>264–301.</para>
          </listitem>
          <listitem id="ch0038s000000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Thomas S, Bennett J, Jack S, Oliver J, Purdie G, Upton A, Baker MG.</emphasis> 2021. Descriptive analysis of group A streptococcus skin swabs and acute rheumatic fever, Auckland, New Zealand, 2010-2016. <emphasis><citetitle>Lancet Reg Health West Pac</citetitle></emphasis> 8<emphasis role="strong">:</emphasis>100101.</para>
          </listitem>
          <listitem id="ch0038s000000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Snider LA, Swedo SE.</emphasis> 2003. Post-streptococcal autoimmune disorders of the central nervous system. <emphasis><citetitle>Curr Opin Neurol</citetitle></emphasis> <emphasis role="strong">16:</emphasis>359–365.</para>
          </listitem>
          <listitem id="ch0038s000000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Nasser W, Beres SB, Olsen RJ, Dean MA, Rice KA, Long SW, Kristinsson KG, Gottfredsson M, Vuopio J, Raisanen K, Caugant DA, Steinbakk M, Low DE, McGeer A, Darenberg J, Henriques-Normark B, Van Beneden CA, Hoffmann S, Musser JM.</emphasis> 2014. Evolutionary pathway to increased virulence and epidemic group A <emphasis><citetitle>Streptococcus</citetitle></emphasis> disease derived from 3,615 genome sequences. <emphasis><citetitle>Proc Natl Acad Sci USA</citetitle></emphasis> <emphasis role="strong">111:</emphasis>E1768–E1776.</para>
          </listitem>
          <listitem id="ch0038s000000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Lacy MD, Horn K.</emphasis> 2009. Nosocomial transmission of invasive group a streptococcus from patient to health care worker. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">49:</emphasis>354–357.</para>
          </listitem>
          <listitem id="ch0038s000000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC).</emphasis> 2010. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. <emphasis><citetitle>MMWR Recomm Rep</citetitle></emphasis> <emphasis role="strong">59</emphasis>(RR-10)<emphasis role="strong">:</emphasis>1–36.</para>
          </listitem>
          <listitem id="ch0038s000000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">The American College of Obstetricians and Gynecologists (ACOG) Committee.</emphasis> 2020. Prevention of group B streptococcal early-onset disease in newborns. ACOG Committee opinion, number 797. <emphasis><citetitle>Obstet Gynecol</citetitle></emphasis> <emphasis role="strong">135:</emphasis>e51–e72.</para>
          </listitem>
          <listitem id="ch0038s000000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Puopolo KM, Lynfield R, Cummings JJ, Hand I, Adams-Chapman I, Poindexter B, Stewart DL, Aucott SW, Goldsmith JP, Mowitz M, Watterberg K, Maldonado YA, Zaoutis TE, Banerjee R, Barnett ED, Campbell JD, Gerber JS, Kourtis AP, Munoz FM, Nolt D, Nyquist A-C, O’Leary ST, Sawyer MH, Steinbach WJ, Zangwill K, Committee on Fetus and Newborn, Committee on Infectious Diseases.</emphasis> 2019. Management of infants at risk for group B streptococcal disease. <emphasis><citetitle>Pediatrics</citetitle></emphasis> <emphasis role="strong">144:</emphasis>e20191881.</para>
          </listitem>
          <listitem id="ch0038s000000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Filkins L, Hauser J, Robinson-Dunn B, Tibbetts R, Boyanton B, Revell P.</emphasis> 2020 (updated July 2021). <emphasis><citetitle>Guidelines for detection and identification of group B streptococcus.</citetitle></emphasis> <ulink url="https://asm.org/Guideline/Guidelines-for-the-Detection-and-Identification-of">https://asm.org/Guideline/Guidelines-for-the-Detection-and-Identification-of</ulink></para>
          </listitem>
          <listitem id="ch0038s000000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, Harrison LH, Lynfield R, Mohle-Boetani J, Zansky S, Albanese BA, Stefonek K, Zell ER, Jackson D, Thompson T, Schrag SJ.</emphasis> 2009. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">49:</emphasis>85–92.</para>
          </listitem>
          <listitem id="ch0038s000000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Sendi P, Johansson L, Norrby-Teglund A.</emphasis> 2008. Invasive group B streptococcal disease in non-pregnant adults: a review with emphasis on skin and soft-tissue infections. <emphasis><citetitle>Infection</citetitle></emphasis> <emphasis role="strong">36:</emphasis>100–111.</para>
          </listitem>
          <listitem id="ch0038s000000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Hule GP, Karmarkar MG, Cameron A, Hase N, Khopkar U, Mehta PR, McNeilly CL, McMillan D, Sriprakash KS.</emphasis> 2015. Seropositivity for antibodies to DRS-G, a virulence factor from <emphasis><citetitle>Streptococcus dysgalactiae</citetitle></emphasis> subsp. <emphasis><citetitle>equisimilis</citetitle></emphasis>, is an independent risk factor for poststreptococcus glomerulonephritis and chronic kidney disease in Mumbai, India. <emphasis><citetitle>Clin Vaccine Immunol</citetitle></emphasis> <emphasis role="strong">22:</emphasis>938–942.</para>
          </listitem>
          <listitem id="ch0038s000000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Haidan A, Talay SR, Rohde M, Sriprakash KS, Currie BJ, Chhatwal GS.</emphasis> 2000. Pharyngeal carriage of group C and group G streptococci and acute rheumatic fever in an Aboriginal population. <emphasis><citetitle>Lancet</citetitle></emphasis> <emphasis role="strong">356:</emphasis>1167–1169.</para>
          </listitem>
          <listitem id="ch0038s000000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Falguera M, Trujillano J, Caro S, Menéndez R, Carratalà J, Ruiz-González A, Vilà M, García M, Porcel JM, Torres A, NAC-CALIDAD (Proyecto Integrado de Investigación de la Sociedad Española de Patología del Aparato Respiratorio sobre Infecciones Respiratorias de Vías Bajas) Study Group.</emphasis> 2009. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">49:</emphasis>409–416.</para>
          </listitem>
          <listitem id="ch0038s000000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Ganaie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW, Gladstone RA, Turner P, Keenan JD, Breiman RF, Nahm MH.</emphasis> 2020. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large <emphasis><citetitle>cps</citetitle></emphasis> fragment from an oral streptococcus. <emphasis><citetitle>mBio</citetitle></emphasis> <emphasis role="strong">11:</emphasis>e00937-20.</para>
          </listitem>
          <listitem id="ch0038s000000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, Poehling KA, Pilishvili T.</emphasis> 2022. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices—United States. <emphasis><citetitle>MMWR Morb Mortal Wkly Rep</citetitle></emphasis> <emphasis role="strong">71:</emphasis>109–117.</para>
          </listitem>
          <listitem id="ch0038s000000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV.</emphasis> 2013. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. <emphasis><citetitle>Emerg Infect Dis</citetitle></emphasis> <emphasis role="strong">19:</emphasis>1074–1083.</para>
          </listitem>
          <listitem id="ch0038s000000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Deloria Knoll M, Bennett JC, Quesada MG, Kagucia EW, Peterson ME, The Pserenade Team, et al.</emphasis> 2021. Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13: the pneumococcal serotype replacement and distribution estimation (PSERENADE) project. <emphasis><citetitle>Microorganisms</citetitle></emphasis> <emphasis role="strong">9:</emphasis>742.</para>
          </listitem>
          <listitem id="ch0038s000000li0035" role="bibliographyEntry">
            <anchor id="ch0038s000000a0128"/>
            <para>35.<emphasis role="strong">Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.</emphasis> 2013. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">57:</emphasis>952–962.</para>
          </listitem>
          <listitem id="ch0038s000000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG, Toronto Bacterial Diseases Network, Canadian Public Health Laboratory Network.</emphasis> 2013. Serotype distribution of invasive <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. <emphasis><citetitle>Can J Microbiol</citetitle></emphasis> <emphasis role="strong">59:</emphasis>778–788.</para>
          </listitem>
          <listitem id="ch0038s000000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Keith ER, Podmore RG, Anderson TP, Murdoch DR.</emphasis> 2006. Characteristics of <emphasis><citetitle>Streptococcus pseudopneumoniae</citetitle></emphasis> isolated from purulent sputum samples. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">44:</emphasis>923–927.</para>
          </listitem>
          <listitem id="ch0038s000000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Doern CD, Burnham CA.</emphasis> 2010. It’s not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">48:</emphasis>3829–3835.</para>
          </listitem>
          <listitem id="ch0038s000000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Parkins MD, Sibley CD, Surette MG, Rabin HR.</emphasis> 2008. The <emphasis><citetitle>Streptococcus milleri</citetitle></emphasis> group—an unrecognized cause of disease in cystic fibrosis: a case series and literature review. <emphasis><citetitle>Pediatr Pulmonol</citetitle></emphasis> <emphasis role="strong">43:</emphasis>490–497.</para>
          </listitem>
          <listitem id="ch0038s000000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Siegman-Igra Y, Azmon Y, Schwartz D.</emphasis> 2012. Milleri group streptococcus—a stepchild in the viridans family. <emphasis><citetitle>Eur J Clin Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">31:</emphasis>2453–2459.</para>
          </listitem>
          <listitem id="ch0038s000000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Whiley RA, Beighton D, Winstanley TG, Fraser HY, Hardie JM.</emphasis> 1992. <emphasis><citetitle>Streptococcus intermedius</citetitle>, <citetitle>Streptococcus constellatus</citetitle></emphasis>, and <emphasis><citetitle>Streptococcus anginosus</citetitle></emphasis> (the <emphasis><citetitle>Streptococcus milleri</citetitle></emphasis> group): association with different body sites and clinical infections. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">30:</emphasis>243–244.</para>
          </listitem>
          <listitem id="ch0038s000000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Corredoira JC, Alonso MP, García JF, Casariego E, Coira A, Rodriguez A, Pita J, Louzao C, Pombo B, López MJ, Varela J.</emphasis> 2005. Clinical characteristics and significance of <emphasis><citetitle>Streptococcus salivarius</citetitle></emphasis> bacteremia and <emphasis><citetitle>Streptococcus bovis</citetitle></emphasis> bacteremia: a prospective 16-year study. <emphasis><citetitle>Eur J Clin Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">24:</emphasis>250–255.</para>
          </listitem>
          <listitem id="ch0038s000000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Caufield PW, Cutter GR, Dasanayake AP.</emphasis> 1993. Initial acquisition of mutans streptococci by infants: evidence for a discrete window of infectivity. <emphasis><citetitle>J Dent Res</citetitle></emphasis> <emphasis role="strong">72:</emphasis>37–45.</para>
          </listitem>
          <listitem id="ch0038s000000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Beck M, Frodl R, Funke G.</emphasis> 2008. Comprehensive study of strains previously designated <emphasis><citetitle>Streptococcus bovis</citetitle></emphasis> consecutively isolated from human blood cultures and emended description of <emphasis><citetitle>Streptococcus gallolyticus</citetitle></emphasis> and <emphasis><citetitle>Streptococcus infantarius</citetitle></emphasis> subsp. coli. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">46:</emphasis>2966–2972.</para>
          </listitem>
          <listitem id="ch0038s000000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Boleij A, van Gelder MM, Swinkels DW, Tjalsma H.</emphasis> 2011. Clinical importance of <emphasis><citetitle>Streptococcus gallolyticus</citetitle></emphasis> infection among colorectal cancer patients: systematic review and meta-analysis. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">53:</emphasis>870–878.</para>
          </listitem>
          <listitem id="ch0038s000000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">World Health Organization.</emphasis> 2005. Outbreak associated with Streptococcus suis in pigs, China. <emphasis><citetitle>Wkly Epidemiol Rec</citetitle></emphasis> <emphasis role="strong">80:</emphasis>269–270.</para>
          </listitem>
          <listitem id="ch0038s000000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Facklam R, Elliott J, Pigott N, Franklin AR.</emphasis> 1995. Identification of <emphasis><citetitle>Streptococcus porcinus</citetitle></emphasis> from human sources. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">33:</emphasis>385–388.</para>
          </listitem>
          <listitem id="ch0038s000000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Bekal S, Gaudreau C, Laurence RA, Simoneau E, Raynal L.</emphasis> 2006. <emphasis><citetitle>Streptococcus pseudoporcinus</citetitle></emphasis> sp. nov., a novel species isolated from the genitourinary tract of women. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">44:</emphasis>2584–2586.</para>
          </listitem>
          <listitem id="ch0038s000000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Suwantarat N, Grundy M, Rubin M, Harris R, Miller JA, Romagnoli M, Hanlon A, Tekle T, Ellis BC, Witter FR, Carroll KC.</emphasis> 2015. Recognition of <emphasis><citetitle>Streptococcus pseudoporcinus</citetitle></emphasis> colonization in women as a consequence of using matrix-assisted laser desorption ionization-time of flight mass spectrometry for group B <emphasis><citetitle>Streptococcus</citetitle></emphasis> identification. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">53:</emphasis>3926–3930.</para>
          </listitem>
          <listitem id="ch0038s000000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Facklam R, Elliott J, Shewmaker L, Reingold A.</emphasis> 2005. Identification and characterization of sporadic isolates of <emphasis><citetitle>Streptococcus iniae</citetitle></emphasis> isolated from humans. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">43:</emphasis>933–937.</para>
          </listitem>
          <listitem id="ch0038s000000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Lau SKP, Curreem SOT, Lin CCN, Fung AMY, Yuen KY, Woo PCY.</emphasis> 2013. <emphasis><citetitle>Streptococcus hongkongensis</citetitle></emphasis> sp. nov., isolated from a patient with an infected puncture wound and from a marine flatfish. <emphasis><citetitle>Int J Syst Evol Microbiol</citetitle></emphasis> <emphasis role="strong">63:</emphasis>2570–2576.</para>
          </listitem>
          <listitem id="ch0038s000000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Shewmaker PL, Whitney AM, Humrighouse BW.</emphasis> 2016. Phenotypic, genotypic, and antimicrobial characteristics of <emphasis><citetitle>Streptococcus halichoeri</citetitle></emphasis> isolates from humans: proposal to rename <emphasis><citetitle>Streptococcus halichoeri</citetitle></emphasis> as <emphasis><citetitle>Streptococcus halichoeri</citetitle></emphasis> subsp. <emphasis><citetitle>halichoeri</citetitle></emphasis>, and description of <emphasis><citetitle>Streptococcus halichoeri</citetitle></emphasis> subsp. <emphasis><citetitle>hominis</citetitle></emphasis> subsp. nov., a bacterium associated with human clinical infections. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">54:</emphasis>739–744.</para>
          </listitem>
          <listitem id="ch0038s000000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Shakir SM, Gill R, Salberg J, Slechta ES, Feldman M, Fritsche T, Clarridge J, Sharp SE, Fisher MA.</emphasis> 2021. Clinical laboratory perspective on <emphasis><citetitle>Streptococcus halichoeri</citetitle></emphasis>, an unusual nonhemolytic, Lancefield group B Streptococcus causing human infections. <emphasis><citetitle>Emerg Infect Dis</citetitle></emphasis> <emphasis role="strong">27:</emphasis>1309–1316.</para>
          </listitem>
          <listitem id="ch0038s000000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Martin DR, Stanhope JM, Finch LA.</emphasis> 1977. Delayed culture of group-A streptococci: an evaluation of variables in methods of examining throat swabs. <emphasis><citetitle>J Med Microbiol</citetitle></emphasis> <emphasis role="strong">10:</emphasis>249–253.</para>
          </listitem>
          <listitem id="ch0038s000000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Stewart EH, Davis B, Clemans-Taylor BL, Littenberg B, Estrada CA, Centor RM.</emphasis> 2014. Rapid antigen group A streptococcus test to diagnose pharyngitis: a systematic review and meta-analysis. <emphasis><citetitle>PLoS One</citetitle></emphasis> <emphasis role="strong">9:</emphasis>e111727.</para>
          </listitem>
          <listitem id="ch0038s000000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, Martin JM, Van Beneden C.</emphasis> 2012. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">55:</emphasis>1279–1282.</para>
          </listitem>
          <listitem id="ch0038s000000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Chapin KC, Blake P, Wilson CD.</emphasis> 2002. Performance characteristics and utilization of rapid antigen test, DNA probe, and culture for detection of group a streptococci in an acute care clinic. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">40:</emphasis>4207–4210.</para>
          </listitem>
          <listitem id="ch0038s000000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Mein J, Lum G.</emphasis> 1999. CSF bacterial antigen detection tests offer no advantage over Gram’s stain in the diagnosis of bacterial meningitis. <emphasis><citetitle>Pathology</citetitle></emphasis> <emphasis role="strong">31:</emphasis>67–69.</para>
          </listitem>
          <listitem id="ch0038s000000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Moïsi JC, Saha SK, Falade AG, Njanpop-Lafourcade BM, Oundo J, Zaidi AK, Afroj S, Bakare RA, Buss JK, Lasi R, Mueller J, Odekanmi AA, Sangaré L, Scott JA, Knoll MD, Levine OS, Gessner BD.</emphasis> 2009. Enhanced diagnosis of pneumococcal meningitis with use of the Binax NOW immunochromatographic test of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> antigen: a multisite study. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">48</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S49–S56.</para>
          </listitem>
          <listitem id="ch0038s000000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Rosón B, Fernández-Sabé N, Carratalà J, Verdaguer R, Dorca J, Manresa F, Gudiol F.</emphasis> 2004. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">38:</emphasis>222–226.</para>
          </listitem>
          <listitem id="ch0038s000000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Andreo F, Prat C, Ruiz-Manzano J, Lores L, Blanco S, Cuesta MA, Giménez M, Domínguez J.</emphasis> 2009. Persistence of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> urinary antigen excretion after pneumococcal pneumonia. <emphasis><citetitle>Eur J Clin Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">28:</emphasis>197–201.</para>
          </listitem>
          <listitem id="ch0038s000000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Dowell SF, Garman RL, Liu G, Levine OS, Yang YH.</emphasis> 2001. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">32:</emphasis>824–825.</para>
          </listitem>
          <listitem id="ch0038s000000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Wang F, Tian Y, Chen L, Luo R, Sickler J, Liesenfeld O, Chen S.</emphasis> 2017. Accurate detection of <emphasis><citetitle>Streptococcus pyogenes</citetitle></emphasis> at the point of care using the Cobas Liat Strep A nucleic acid test. <emphasis><citetitle>Clin Pediatr (Phila)</citetitle></emphasis> <emphasis role="strong">56:</emphasis>1128–1134.</para>
          </listitem>
          <listitem id="ch0038s000000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Anderson NW, Buchan BW, Mayne D, Mortensen JE, Mackey TL, Ledeboer NA.</emphasis> 2013. Multicenter clinical evaluation of the Illumigene group A <emphasis><citetitle>Streptococcus</citetitle></emphasis> DNA amplification assay for detection of group A <emphasis><citetitle>Streptococcus</citetitle></emphasis> from pharyngeal swabs. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">51:</emphasis>1474–1477.</para>
          </listitem>
          <listitem id="ch0038s000000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Carvalho MG, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, Steigerwalt A, Whaley M, Facklam RR, Fields B, Carlone G, Ades EW, Dagan R, Sampson JS.</emphasis> 2007. Evaluation and improvement of real-time PCR assays targeting <emphasis><citetitle>lytA</citetitle>, <citetitle>ply</citetitle></emphasis>, and <emphasis><citetitle>psaA</citetitle></emphasis> genes for detection of pneumococcal DNA. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">45:</emphasis>2460–2466.</para>
          </listitem>
          <listitem id="ch0038s000000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Trzciński K, Bogaert D, Wyllie A, Chu MLJN, van der Ende A, Bruin JP, van den Dobbelsteen G, Veenhoven RH, Sanders EAM.</emphasis> 2013. Superiority of trans-oral over trans-nasal sampling in detecting <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> colonization in adults. <emphasis><citetitle>PLoS One</citetitle></emphasis> <emphasis role="strong">8:</emphasis>e60520.</para>
          </listitem>
          <listitem id="ch0038s000000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Tavares DA, Handem S, Carvalho RJ, Paulo AC, de Lencastre H, Hinds J, Sá-Leão R.</emphasis> 2019. Identification of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> by a real-time PCR assay targeting SP2020. <emphasis><citetitle>Sci Rep</citetitle></emphasis> <emphasis role="strong">9:</emphasis>3285.</para>
          </listitem>
          <listitem id="ch0038s000000li0068" role="bibliographyEntry">
            <anchor id="ch0038s000000a0129"/>
            <para>68.<emphasis role="strong">Driscoll AJ, Karron RA, Bhat N, Thumar B, Kodani M, Fields BS, Whitney CG, Levine OS, O’Brien KL, Murdoch DR.</emphasis> 2014. Evaluation of fast-track diagnostics and TaqMan array card real-time PCR assays for the detection of respiratory pathogens. <emphasis><citetitle>J Microbiol Methods</citetitle></emphasis> <emphasis role="strong">107:</emphasis>222–226.</para>
          </listitem>
          <listitem id="ch0038s000000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Alby K, Mitchell SL.</emphasis> 2018. Lower respiratory multiplex panels for the detection of bacterial and viral infections. <emphasis><citetitle>Clin Microbiol Newsl</citetitle></emphasis> <emphasis role="strong">40:</emphasis>131–136.</para>
          </listitem>
          <listitem id="ch0038s000000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Leber AL, Everhart K, Balada-Llasat JM, Cullison J, Daly J, Holt S, Lephart P, Salimnia H, Schreckenberger PC, DesJarlais S, Reed SL, Chapin KC, LeBlanc L, Johnson JK, Soliven NL, Carroll KC, Miller JA, Dien Bard J, Mestas J, Bankowski M, Enomoto T, Hemmert AC, Bourzac KM.</emphasis> 2016. Multicenter evaluation of BioFire FilmArray meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">54:</emphasis>2251–2261.</para>
          </listitem>
          <listitem id="ch0038s000000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Beckman M, Washam MC, DeBurger B, Haslam DB, Courter JD, Andersen H, Schaffzin JK, Tchou MJ, Ankrum A, Mortensen J.</emphasis> 2019. Reliability of the Verigene system for the identification for Gram-positive bacteria and detection of antimicrobial resistance markers from children with bacteremia. <emphasis><citetitle>Diagn Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">93:</emphasis>191–195.</para>
          </listitem>
          <listitem id="ch0038s000000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Oberhettinger P, Zieger J, Autenrieth I, Marschal M, Peter S.</emphasis> 2020. Evaluation of two rapid molecular test systems to establish an algorithm for fast identification of bacterial pathogens from positive blood cultures. <emphasis><citetitle>Eur J Clin Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">39:</emphasis>1147–1157.</para>
          </listitem>
          <listitem id="ch0038s000000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Arbique JC, Poyart C, Trieu-Cuot P, Quesne G, Carvalho MG, Steigerwalt AG, Morey RE, Jackson D, Davidson RJ, Facklam RR.</emphasis> 2004. Accuracy of phenotypic and genotypic testing for identification of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> and description of <emphasis><citetitle>Streptococcus pseudopneumoniae</citetitle></emphasis> sp. nov. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">42:</emphasis>4686–4696.</para>
          </listitem>
          <listitem id="ch0038s000000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Murray PR, Wold AD, Schreck CA, Washington JA II.</emphasis> 1976. Effects of selective media and atmosphere of incubation on the isolation of group A streptococci. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">4:</emphasis>54–56.</para>
          </listitem>
          <listitem id="ch0038s000000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Bisno AL.</emphasis> 2001. Acute pharyngitis. <emphasis><citetitle>N Engl J Med</citetitle></emphasis> <emphasis role="strong">344:</emphasis>205–211.</para>
          </listitem>
          <listitem id="ch0038s000000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Kellogg JA.</emphasis> 1990. Suitability of throat culture procedures for detection of group A streptococci and as reference standards for evaluation of streptococcal antigen detection kits. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">28:</emphasis>165–169.</para>
          </listitem>
          <listitem id="ch0038s000000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Van TT, Mata K, Dien Bard J.</emphasis> 2019. Automated detection of <emphasis><citetitle>Streptococcus pyogenes</citetitle></emphasis> pharyngitis by use of Colorex StrepA CHROMagar and WASPLab artificial intelligence chromogenic detection module software. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">57:</emphasis>e00811-19.</para>
          </listitem>
          <listitem id="ch0038s000000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Block T, Munson E, Culver A, Vaughan K, Hryciuk JE.</emphasis> 2008. Comparison of carrot broth- and selective Todd-Hewitt broth-enhanced PCR protocols for real-time detection of <emphasis><citetitle>Streptococcus agalactiae</citetitle></emphasis> in prenatal vaginal/anorectal specimens. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">46:</emphasis>3615–3620.</para>
          </listitem>
          <listitem id="ch0038s000000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV.</emphasis> 2008. Accuracy of phenotypic methods for identification of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> isolates included in surveillance programs. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">46:</emphasis>2184–2188.</para>
          </listitem>
          <listitem id="ch0038s000000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Fan WT, Qin TT, Bi RR, Kang HQ, Ma P, Gu B.</emphasis> 2017. Performance of the matrix-assisted laser desorption ionization time-of-flight mass spectrometry system for rapid identification of streptococci: a review. <emphasis><citetitle>Eur J Clin Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">36:</emphasis>1005–1012.</para>
          </listitem>
          <listitem id="ch0038s000000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Nybakken EJ, Oppegaard O, Gilhuus M, Jensen CS, Mylvaganam H.</emphasis> 2021. Identification of <emphasis><citetitle>Streptococcus dysgalactiae</citetitle></emphasis> using matrix-assisted laser desorption/ionization-time of flight mass spectrometry; refining the database for improved identification. <emphasis><citetitle>Diagn Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">99:</emphasis>115207.</para>
          </listitem>
          <listitem id="ch0038s000000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Harju I, Lange C, Kostrzewa M, Maier T, Rantakokko-Jalava K, Haanperä M.</emphasis> 2017. Improved differentiation of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> and other <emphasis><citetitle>S. mitis</citetitle></emphasis> group streptococci by MALDI biotyper using an improved MALDI Biotyper database content and a novel result interpretation algorithm. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">55:</emphasis>914–922.</para>
          </listitem>
          <listitem id="ch0038s000000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Dubois D, Segonds C, Prere MF, Marty N, Oswald E.</emphasis> 2013. Identification of clinical <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> isolates among other alpha and nonhemolytic streptococci by use of the Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry system. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">51:</emphasis>1861–1867.</para>
          </listitem>
          <listitem id="ch0038s000000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Mihaila-Amrouche L, Bouvet A, Loubinoux J.</emphasis> 2004. Clonal spread of emm type 28 isolates of <emphasis><citetitle>Streptococcus pyogenes</citetitle></emphasis> that are multiresistant to antibiotics. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">42:</emphasis>3844–3846.</para>
          </listitem>
          <listitem id="ch0038s000000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Pires R, Rolo D, Mato R, Feio de Almeida J, Johansson C, Henriques-Normark B, Morais A, Brito-Avô A, Gonçalo-Marques J, Santos-Sanches I.</emphasis> 2009. Resistance to bacitracin in <emphasis><citetitle>Streptococcus pyogenes</citetitle></emphasis> from oropharyngeal colonization and noninvasive infections in Portugal was caused by two clones of distinct virulence genotypes. <emphasis><citetitle>FEMS Microbiol Lett</citetitle></emphasis> <emphasis role="strong">296:</emphasis>235–240.</para>
          </listitem>
          <listitem id="ch0038s000000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Ratner HB, Weeks LS, Stratton CW.</emphasis> 1986. Evaluation of spot CAMP test for identification of group B streptococci. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">24:</emphasis>296–297.</para>
          </listitem>
          <listitem id="ch0038s000000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Gorm Jensen T, Bossen Konradsen H, Bruun B.</emphasis> 1999. Evaluation of the Rapid ID 32 Strep system. <emphasis><citetitle>Clin Microbiol Infect</citetitle></emphasis> <emphasis role="strong">5:</emphasis>417–423.</para>
          </listitem>
          <listitem id="ch0038s000000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Haanperä M, Jalava J, Huovinen P, Meurman O, Rantakokko-Jalava K.</emphasis> 2007. Identification of alpha-hemolytic streptococci by pyrosequencing the 16S rRNA gene and by use of VITEK 2. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">45:</emphasis>762–770.</para>
          </listitem>
          <listitem id="ch0038s000000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Teles C, Smith A, Ramage G, Lang S.</emphasis> 2011. Identification of clinically relevant viridans group streptococci by phenotypic and genotypic analysis. <emphasis><citetitle>Eur J Clin Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">30:</emphasis>243–250.</para>
          </listitem>
          <listitem id="ch0038s000000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Poyart C, Quesne G, Coulon S, Berche P, Trieu-Cuot P.</emphasis> 1998. Identification of streptococci to species level by sequencing the gene encoding the manganese-dependent superoxide dismutase. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">36:</emphasis>41–47.</para>
          </listitem>
          <listitem id="ch0038s000000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Summanen PH, Rowlinson MC, Wooton J, Finegold SM.</emphasis> 2009. Evaluation of genotypic and phenotypic methods for differentiation of the members of the Anginosus group streptococci. <emphasis><citetitle>Eur J Clin Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">28:</emphasis>1123–1128.</para>
          </listitem>
          <listitem id="ch0038s000000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Whiley RA, Fraser H, Hardie JM, Beighton D.</emphasis> 1990. Phenotypic differentiation of <emphasis><citetitle>Streptococcus intermedius</citetitle>, <citetitle>Streptococcus constellatus</citetitle></emphasis>, and <emphasis><citetitle>Streptococcus anginosus</citetitle></emphasis> strains within the “<emphasis><citetitle>Streptococcus milleri</citetitle></emphasis> group”. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">28:</emphasis>1497–1501.</para>
          </listitem>
          <listitem id="ch0038s000000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Slotved HC, Facklam RR, Fuursted K.</emphasis> 2017. Assessment of a novel bile solubility test and MALDI-TOF for the differentiation of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> from other mitis group streptococci. <emphasis><citetitle>Sci Rep</citetitle></emphasis> <emphasis role="strong">7:</emphasis>7167.</para>
          </listitem>
          <listitem id="ch0038s000000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Chuard C, Reller LB.</emphasis> 1998. Bile-esculin test for presumptive identification of enterococci and streptococci: effects of bile concentration, inoculation technique, and incubation time. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">36:</emphasis>1135–1136.</para>
          </listitem>
          <listitem id="ch0038s000000li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Homer KA, Denbow L, Whiley RA, Beighton D.</emphasis> 1993. Chondroitin sulfate depolymerase and hyaluronidase activities of viridans streptococci determined by a sensitive spectrophotometric assay. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">31:</emphasis>1648–1651.</para>
          </listitem>
          <listitem id="ch0038s000000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Maiden MC.</emphasis> 2006. Multilocus sequence typing of bacteria. <emphasis><citetitle>Annu Rev Microbiol</citetitle></emphasis> <emphasis role="strong">60:</emphasis>561–588.</para>
          </listitem>
          <listitem id="ch0038s000000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E, Collins M, Donohoe K, Harris D, Murphy L, Quail MA, Samuel G, Skovsted IC, Kaltoft MS, Barrell B, Reeves PR, Parkhill J, Spratt BG.</emphasis> 2006. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. <emphasis><citetitle>PLoS Genet</citetitle></emphasis> <emphasis role="strong">2:</emphasis>e31.</para>
          </listitem>
          <listitem id="ch0038s000000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Epping L, van Tonder AJ, Gladstone RA, The Global Pneumococcal Sequencing Consortium, Bentley SD, Page AJ, Keane JA.</emphasis> 2018. SeroBA: rapid high-throughput serotyping of <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> from whole genome sequence data. <emphasis><citetitle>Microb Genom</citetitle></emphasis> <emphasis role="strong">4:</emphasis>e000204.</para>
          </listitem>
          <listitem id="ch0038s000000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Kapatai G, Sheppard CL, Al-Shahib A, Litt DJ, Underwood AP, Harrison TG, Fry NK.</emphasis> 2016. Whole genome sequencing of <emphasis><citetitle>Streptococcus pneumoniae:</citetitle></emphasis> development, evaluation and verification of targets for serogroup and serotype prediction using an automated pipeline. <emphasis><citetitle>PeerJ</citetitle></emphasis> <emphasis role="strong">4:</emphasis>e2477.</para>
          </listitem>
          <listitem id="ch0038s000000li0100" role="bibliographyEntry">
            <anchor id="ch0038s000000a0130"/>
            <para>100.<emphasis role="strong">Metcalf BJ, et al, Active Bacterial Core surveillance team.</emphasis> 2017. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive <emphasis><citetitle>Streptococcus agalactiae</citetitle></emphasis> recovered in the USA. <emphasis><citetitle>Clin Microbiol Infect</citetitle></emphasis> <emphasis role="strong">23:</emphasis>574.e7–574.e14.</para>
          </listitem>
          <listitem id="ch0038s000000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Metcalf BJ, et al, Active Bacterial Core surveillance team.</emphasis> 2016. Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States. <emphasis><citetitle>Clin Microbiol Infect</citetitle></emphasis> <emphasis role="strong">22:</emphasis>1002.e1–1002.e8.</para>
          </listitem>
          <listitem id="ch0038s000000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Jolley KA, Maiden MCJ.</emphasis> 2010. BIGSdb: scalable analysis of bacterial genome variation at the population level. <emphasis><citetitle>BMC Bioinformatics</citetitle></emphasis> <emphasis role="strong">11:</emphasis>595.</para>
          </listitem>
          <listitem id="ch0038s000000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Li Y, Rivers J, Mathis S, Li Z, Velusamy S, Nanduri SA, Van Beneden CA, Snippes-Vagnone P, Lynfield R, McGee L, Chochua S, Metcalf BJ, Beall B.</emphasis> 2020. Genomic surveillance of <emphasis><citetitle>Streptococcus pyogenes</citetitle></emphasis> strains causing invasive disease, United States, 2016–2017. <emphasis><citetitle>Front Microbiol</citetitle></emphasis> <emphasis role="strong">11:</emphasis>1547.</para>
          </listitem>
          <listitem id="ch0038s000000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Tagini F, Greub G.</emphasis> 2017. Bacterial genome sequencing in clinical microbiology: a pathogen-oriented review. <emphasis><citetitle>Eur J Clin Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">36:</emphasis>2007–2020.</para>
          </listitem>
          <listitem id="ch0038s000000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Chochua S, Metcalf BJ, Li Z, Rivers J, Mathis S, Jackson D, Gertz RE Jr, Srinivasan V, Lynfield R, Van Beneden C, McGee L, Beall B.</emphasis> 2017. Population and whole genome sequence based characterization of invasive group A streptococci recovered in the United States during 2015. <emphasis><citetitle>mBio</citetitle></emphasis> <emphasis role="strong">8:</emphasis>e01422-177.</para>
          </listitem>
          <listitem id="ch0038s000000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Dickinson H, Reacher M, Nazareth B, Eagle H, Fowler D, Underwood A, Chand M, Chalker V, Coelho J, Daniel R, Kapatai G, Al-Shabib A, Puleston R.</emphasis> 2019. Whole-genome sequencing in the investigation of recurrent invasive group A streptococcus outbreaks in a maternity unit. <emphasis><citetitle>J Hosp Infect</citetitle></emphasis> <emphasis role="strong">101:</emphasis>320–326.</para>
          </listitem>
          <listitem id="ch0038s000000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Austrian R.</emphasis> 1976. The Quellung reaction, a neglected microbiologic technique. <emphasis><citetitle>Mt Sinai J Med</citetitle></emphasis> <emphasis role="strong">43:</emphasis>699–709.</para>
          </listitem>
          <listitem id="ch0038s000000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Slotved HC, Kaltoft M, Skovsted IC, Kerrn MB, Espersen F.</emphasis> 2004. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex). <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">42:</emphasis>2518–2522.</para>
          </listitem>
          <listitem id="ch0038s000000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Massire C, Gertz RE Jr, Svoboda P, Levert K, Reed MS, Pohl J, Kreft R, Li F, White N, Ranken R, Blyn LB, Ecker DJ, Sampath R, Beall B.</emphasis> 2012. Concurrent serotyping and genotyping of pneumococci by use of PCR and electrospray ionization mass spectrometry. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">50:</emphasis>2018–2025.</para>
          </listitem>
          <listitem id="ch0038s000000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Kong F, Brown M, Sabananthan A, Zeng X, Gilbert GL.</emphasis> 2006. Multiplex PCR-based reverse line blot hybridization assay to identify 23 <emphasis><citetitle>Streptococcus pneumoniae</citetitle></emphasis> polysaccharide vaccine serotypes. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">44:</emphasis>1887–1891.</para>
          </listitem>
          <listitem id="ch0038s000000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Benson JA, Flores AE, Baker CJ, Hillier SL, Ferrieri P.</emphasis> 2002. Improved methods for typing nontypeable isolates of group B streptococci. <emphasis><citetitle>Int J Med Microbiol</citetitle></emphasis> <emphasis role="strong">292:</emphasis>37–42.</para>
          </listitem>
          <listitem id="ch0038s000000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Kong F, Gowan S, Martin D, James G, Gilbert GL.</emphasis> 2002. Serotype identification of group B streptococci by PCR and sequencing. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">40:</emphasis>216–226.</para>
          </listitem>
          <listitem id="ch0038s000000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Poyart C, Tazi A, Réglier-Poupet H, Billoët A, Tavares N, Raymond J, Trieu-Cuot P.</emphasis> 2007. Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">45:</emphasis>1985–1988.</para>
          </listitem>
          <listitem id="ch0038s000000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, Manetti AG, Maggi T, Taddei AR, Grandi G, Telford JL.</emphasis> 2005. Group A <emphasis><citetitle>Streptococcus</citetitle></emphasis> produce pilus-like structures containing protective antigens and Lancefield T antigens. <emphasis><citetitle>Proc Natl Acad Sci USA</citetitle></emphasis> <emphasis role="strong">102:</emphasis>15641–15646.</para>
          </listitem>
          <listitem id="ch0038s000000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Fischetti VA.</emphasis> 1989. Streptococcal M protein: molecular design and biological behavior. <emphasis><citetitle>Clin Microbiol Rev</citetitle></emphasis> <emphasis role="strong">2:</emphasis>285–314.</para>
          </listitem>
          <listitem id="ch0038s000000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Facklam RF, Martin DR, Lovgren M, Johnson DR, Efstratiou A, Thompson TA, Gowan S, Kriz P, Tyrrell GJ, Kaplan E, Beall B.</emphasis> 2002. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">34:</emphasis>28–38.</para>
          </listitem>
          <listitem id="ch0038s000000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Sanderson-Smith M, De Oliveira DM, Guglielmini J, McMillan DJ, Vu T, Holien JK, Henningham A, Steer AC, Bessen DE, Dale JB, Curtis N, Beall BW, Walker MJ, Parker MW, Carapetis JR, Van Melderen L, Sriprakash KS, Smeesters PR, M Protein Study Group.</emphasis> 2014. A systematic and functional classification of <emphasis><citetitle>Streptococcus pyogenes</citetitle></emphasis> that serves as a new tool for molecular typing and vaccine development. <emphasis><citetitle>J Infect Dis</citetitle></emphasis> <emphasis role="strong">210:</emphasis>1325–1338.</para>
          </listitem>
          <listitem id="ch0038s000000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Kapatai G, Coelho J, Platt S, Chalker VJ.</emphasis> 2017. Whole genome sequencing of group A <emphasis><citetitle>Streptococcus</citetitle></emphasis>: development and evaluation of an automated pipeline for <emphasis><citetitle>emm</citetitle></emphasis> gene typing. <emphasis><citetitle>PeerJ</citetitle></emphasis> <emphasis role="strong">5:</emphasis>e3226.</para>
          </listitem>
          <listitem id="ch0038s000000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Enright MC, Spratt BG, Kalia A, Cross JH, Bessen DE.</emphasis> 2001. Multilocus sequence typing of <emphasis><citetitle>Streptococcus pyogenes</citetitle></emphasis> and the relationships between emm type and clone. <emphasis><citetitle>Infect Immun</citetitle></emphasis> <emphasis role="strong">69:</emphasis>2416–2427.</para>
          </listitem>
          <listitem id="ch0038s000000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Shet A, Kaplan EL.</emphasis> 2002. Clinical use and interpretation of group A streptococcal antibody tests: a practical approach for the pediatrician or primary care physician. <emphasis><citetitle>Pediatr Infect Dis J</citetitle></emphasis> <emphasis role="strong">21:</emphasis>420–426.</para>
          </listitem>
          <listitem id="ch0038s000000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Ayoub EM, Nelson B, Shulman ST, Barrett DJ, Campbell JD, Armstrong G, Lovejoy J, Angoff GH, Rockenmacher S.</emphasis> 2003. Group A streptococcal antibodies in subjects with or without rheumatic fever in areas with high or low incidences of rheumatic fever. <emphasis><citetitle>Clin Diagn Lab Immunol</citetitle></emphasis> <emphasis role="strong">10:</emphasis>886–890.</para>
          </listitem>
          <listitem id="ch0038s000000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Kaplan EL, Rothermel CD, Johnson DR.</emphasis> 1998. Antistreptolysin O and anti-deoxyribonuclease B titers: normal values for children ages 2 to 12 in the United States. <emphasis><citetitle>Pediatrics</citetitle></emphasis> <emphasis role="strong">101:</emphasis>86–88.</para>
          </listitem>
          <listitem id="ch0038s000000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Dahesh S, Hensler ME, Van Sorge NM, Gertz RE Jr, Schrag S, Nizet V, Beall BW.</emphasis> 2008. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. <emphasis><citetitle>Antimicrob Agents Chemother</citetitle></emphasis> <emphasis role="strong">52:</emphasis>2915–2918.</para>
          </listitem>
          <listitem id="ch0038s000000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, Nagano N, Kato H, Shibayama K, Arakawa Y.</emphasis> 2008. First molecular characterization of group B streptococci with reduced penicillin susceptibility. <emphasis><citetitle>Antimicrob Agents Chemother</citetitle></emphasis> <emphasis role="strong">52:</emphasis>2890–2897.</para>
          </listitem>
          <listitem id="ch0038s000000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Desjardins M, Delgaty KL, Ramotar K, Seetaram C, Toye B.</emphasis> 2004. Prevalence and mechanisms of erythromycin resistance in group A and group B <emphasis><citetitle>Streptococcus</citetitle></emphasis>: implications for reporting susceptibility results. <emphasis><citetitle>J Clin Microbiol</citetitle></emphasis> <emphasis role="strong">42:</emphasis>5620–5623.</para>
          </listitem>
          <listitem id="ch0038s000000li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Francois Watkins LK, McGee L, Schrag SJ, Beall B, Jain JH, Pondo T, Farley MM, Harrison LH, Zansky SM, Baumbach J, Lynfield R, Snippes Vagnone P, Miller LA, Schaffner W, Thomas AR, Watt JP, Petit S, Langley GE.</emphasis> 2019. Epidemiology of invasive group B streptococcal infections among nonpregnant adults in the United States, 2008-2016. <emphasis><citetitle>JAMA Intern Med</citetitle></emphasis> <emphasis role="strong">179:</emphasis>479–488.</para>
          </listitem>
          <listitem id="ch0038s000000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Park C, Nichols M, Schrag SJ.</emphasis> 2014. Two cases of invasive vancomycin-resistant group B streptococcus infection. <emphasis><citetitle>N Engl J Med</citetitle></emphasis> <emphasis role="strong">370:</emphasis>885–886.</para>
          </listitem>
          <listitem id="ch0038s000000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Srinivasan V, Metcalf BJ, Knipe KM, Ouattara M, McGee L, Shewmaker PL, Glennen A, Nichols M, Harris C, Brimmage M, Ostrowsky B, Park CJ, Schrag SJ, Frace MA, Sammons SA, Beall B.</emphasis> 2014. vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to <emphasis><citetitle>Streptococcus agalactiae</citetitle></emphasis> and <emphasis><citetitle>Streptococcus anginosus</citetitle></emphasis>. <emphasis><citetitle>mBio</citetitle></emphasis> <emphasis role="strong">5:</emphasis>e01386-14.</para>
          </listitem>
          <listitem id="ch0038s000000li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Tazi A, Gueudet T, Varon E, Gilly L, Trieu-Cuot P, Poyart C.</emphasis> 2008. Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis. <emphasis><citetitle>Emerg Infect Dis</citetitle></emphasis> <emphasis role="strong">14:</emphasis>349–350.</para>
          </listitem>
          <listitem id="ch0038s000000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Wang H, Zhao C, He W, Zhang F, Zhang L, Cao B, Sun Z, Xu Y, Yang Q, Mei Y, Hu B, Chu Y, Liao K, Yu Y, Hu Z, Ni Y.</emphasis> 2013. High prevalence of fluoroquinolone-resistant group B streptococci among clinical isolates in China and predominance of sequence type 19 with serotype III. <emphasis><citetitle>Antimicrob Agents Chemother</citetitle></emphasis> <emphasis role="strong">57:</emphasis>1538–1541.</para>
          </listitem>
          <listitem id="ch0038s000000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN.</emphasis> 2015. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. <emphasis><citetitle>Diagn Microbiol Infect Dis</citetitle></emphasis> <emphasis role="strong">81:</emphasis>275–279.</para>
          </listitem>
          <listitem id="ch0038s000000li0132" role="bibliographyEntry">
            <anchor id="ch0038s000000a0131"/>
            <para>132.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2022. <emphasis><citetitle>Performance Standards for Antimicrobial Susceptibility Testing</citetitle></emphasis>. 32nd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0038s000000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE.</emphasis> 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. <emphasis><citetitle>N Engl J Med</citetitle></emphasis> <emphasis role="strong">346:</emphasis>747–750.</para>
          </listitem>
          <listitem id="ch0038s000000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG.</emphasis> 2019. Diagnosis and treatment of adults with community-acquired pneumonia. <emphasis><citetitle>Am J Respir Crit Care Med</citetitle></emphasis> <emphasis role="strong">200:</emphasis>e45–e67.</para>
          </listitem>
          <listitem id="ch0038s000000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.</emphasis> 2018. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. <emphasis><citetitle>J Antimicrob Chemother</citetitle></emphasis> <emphasis role="strong">73:</emphasis>2748–2756.</para>
          </listitem>
          <listitem id="ch0038s000000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">García-de-la-Mària C, Pericas JM, Del Río A, Castañeda X, Vila-Farrés X, Armero Y, Espinal PA, Cervera C, Soy D, Falces C, Ninot S, Almela M, Mestres CA, Gatell JM, Vila J, Moreno A, Marco F, Miró JM, Hospital Clinic Experimental Endocarditis Study Group.</emphasis> 2013. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group streptococci after exposure to daptomycin. <emphasis><citetitle>Antimicrob Agents Chemother</citetitle></emphasis> <emphasis role="strong">57:</emphasis>2319–2325.</para>
          </listitem>
          <listitem id="ch0038s000000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Poyart C, Pierre C, Quesne G, Pron B, Berche P, Trieu-Cuot P.</emphasis> 1997. Emergence of vancomycin resistance in the genus <emphasis><citetitle>Streptococcus</citetitle></emphasis>: characterization of a vanB transferable determinant in <emphasis><citetitle>Streptococcus bovis</citetitle></emphasis>. <emphasis><citetitle>Antimicrob Agents Chemother</citetitle></emphasis> <emphasis role="strong">41:</emphasis>24–29.</para>
          </listitem>
          <listitem id="ch0038s000000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">van’t Wout JW, Bijlmer HA.</emphasis> 2005. Bacteremia due to <emphasis><citetitle>Streptococcus gallolyticus</citetitle></emphasis>, or the perils of revised nomenclature in bacteriology. <emphasis><citetitle>Clin Infect Dis</citetitle></emphasis> <emphasis role="strong">40:</emphasis>1070–1071.</para>
          </listitem>
        </itemizedlist>
        <orderedlist role="notesList">
          <listitem role="noteEntry">
            <para><anchor id="ch0038s000000a0132"/><link linkend="ch0038s000000a0001">*</link>This chapter has been updated from the previous version, authored by Barbara Spellerberg, Claudia Brandt, and Parham Sendi. The work of those authors is acknowledged as the basis of the current version.</para>
          </listitem>
        </orderedlist>
      </sect2>
    </sect1>
  </chapter>
